{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,7]],"date-time":"2026-10-07T20:23:55Z","timestamp":1791404635698,"version":"4.3.3"},"reference-count":393,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2022,6,1]],"date-time":"2022-06-01T00:00:00Z","timestamp":1654041600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2022,6,1]],"date-time":"2022-06-01T00:00:00Z","timestamp":1654041600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2022,4,8]],"date-time":"2022-04-08T00:00:00Z","timestamp":1649376000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Advanced Drug Delivery Reviews"],"published-print":{"date-parts":[[2022,6]]},"DOI":"10.1016\/j.addr.2022.114280","type":"journal-article","created":{"date-parts":[[2022,4,8]],"date-time":"2022-04-08T20:55:02Z","timestamp":1649451302000},"page":"114280","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":90,"special_numbering":"C","title":["Medical devices, smart drug delivery, wearables and technology for the treatment of Diabetes Mellitus"],"prefix":"10.1016","volume":"185","author":[{"given":"Daniel A.","family":"Domingo-Lopez","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giulia","family":"Lattanzi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lucien","family":"H. J. Schreiber","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eimear J.","family":"Wallace","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Robert","family":"Wylie","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Janice","family":"O'Sullivan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eimear B.","family":"Dolan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Garry P.","family":"Duffy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.addr.2022.114280_b0005","doi-asserted-by":"crossref","unstructured":"Classification and diagnosis of diabetes: Standards of medical care in Diabetes - 2018, Diabetes Care. 41 (2018) S13\u2013S27. https:\/\/doi.org\/10.2337\/dc18-S002.","DOI":"10.2337\/dc18-S002"},{"key":"10.1016\/j.addr.2022.114280_b0010","series-title":"Physiology","author":"ElSayed","year":"2018"},{"key":"10.1016\/j.addr.2022.114280_b0015","unstructured":"IDF Diabetes Atlas | Tenth Edition, Int. Diabetes Fed. (2021). https:\/\/diabetesatlas.org\/ (accessed February 21, 2022)."},{"key":"10.1016\/j.addr.2022.114280_b0020","doi-asserted-by":"crossref","first-page":"2449","DOI":"10.1016\/S0140-6736(18)31320-5","article-title":"Type 1 diabetes","volume":"391","author":"DiMeglio","year":"2018","journal-title":"Lancet."},{"key":"10.1016\/j.addr.2022.114280_b0025","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1007\/s00125-002-1009-0","article-title":"The relative contributions of insulin resistance and beta-cell dysfunction to the pathophysiology of Type 2 diabetes","volume":"46","author":"Kahn","year":"2003","journal-title":"Diabetologia."},{"key":"10.1016\/j.addr.2022.114280_b0030","doi-asserted-by":"crossref","first-page":"150","DOI":"10.1016\/j.diabres.2013.11.001","article-title":"Global estimates of undiagnosed diabetes in adults","volume":"103","author":"Beagley","year":"2014","journal-title":"Diabetes Res. Clin. Pract."},{"key":"10.1016\/j.addr.2022.114280_b0035","first-page":"281","article-title":"The current total economic burden of diabetes mellitus in the Netherlands","volume":"75","author":"Peters","year":"2017","journal-title":"Neth. J. Med."},{"key":"10.1016\/j.addr.2022.114280_b0040","doi-asserted-by":"crossref","first-page":"917","DOI":"10.2337\/dci18-0007","article-title":"Economic costs of diabetes in the U.S. in 2017","volume":"41","author":"Yang","year":"2018","journal-title":"Diabetes Care."},{"key":"10.1016\/j.addr.2022.114280_b0045","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1089\/dia.2019.0398","article-title":"Estimated Lifetime Economic Burden of Type 1 Diabetes","volume":"22","author":"Sussman","year":"2020","journal-title":"Diabetes Technol. Ther."},{"key":"10.1016\/j.addr.2022.114280_b0050","doi-asserted-by":"crossref","first-page":"S55","DOI":"10.2337\/dc18-S006","article-title":"Glycemic targets: standards of medical care in Diabetesd","volume":"41","author":"American Diabetes Association","year":"2018","journal-title":"Diabetes Care."},{"key":"10.1016\/j.addr.2022.114280_b0055","unstructured":"National Institute for Health and Care Excellence, Type 1 diabetes in adults: diagnosis and management, NICE, 2016. https:\/\/www.nice.org.uk\/guidance\/ng17\/chapter\/1-Recommendations (accessed December 30, 2019)."},{"key":"10.1016\/j.addr.2022.114280_b0060","unstructured":"National Institute for Health and Care Excellence, Type 2 diabetes in adults: management, NICE, 2019. https:\/\/www.nice.org.uk\/guidance\/ng28\/chapter\/1-Recommendations#blood-glucose-management-2 (accessed December 30, 2019)."},{"key":"10.1016\/j.addr.2022.114280_b0065","unstructured":"National Institute for Health and Care Excellence, Diabetes (type 1 and type 2) in children and young people: diagnosis and management, NICE, 2016. https:\/\/www.nice.org.uk\/guidance\/ng18\/chapter\/Key-priorities-for-implementation#insulin-therapy-for-children-and-young-people-with-type-1-diabetes (accessed December 30, 2019)."},{"key":"10.1016\/j.addr.2022.114280_b0070","unstructured":"National Institute for Health and Care Excellence, Diabetes in pregnancy\u00a0: management from preconception to the postnatal period, NICE. (2015) 2\u201365. http:\/\/www.nice.org.uk\/guidance\/ng3\/chapter\/1-recommendations (accessed December 30, 2019)."},{"key":"10.1016\/j.addr.2022.114280_b0075","doi-asserted-by":"crossref","first-page":"66","DOI":"10.1089\/dia.2018.0384","article-title":"State of Type 1 Diabetes Management and Outcomes from the T1D Exchange in 2016\u20132018","volume":"21","author":"Foster","year":"2019","journal-title":"Diabetes Technol. Ther."},{"key":"10.1016\/j.addr.2022.114280_b0080","doi-asserted-by":"crossref","first-page":"641","DOI":"10.1016\/j.ecl.2010.05.003","article-title":"Hypoglycemia in type 1 diabetes mellitus","volume":"39","author":"Cryer","year":"2010","journal-title":"Endocrinol. Metab. Clin. North Am."},{"key":"10.1016\/j.addr.2022.114280_b0085","doi-asserted-by":"crossref","first-page":"2667","DOI":"10.1016\/j.celrep.2018.02.032","article-title":"\u03b1 Cell Function and Gene Expression Are Compromised in Type 1 Diabetes","volume":"22","author":"Brissova","year":"2018","journal-title":"Cell Rep."},{"key":"10.1016\/j.addr.2022.114280_b0090","doi-asserted-by":"crossref","unstructured":"J.-F. Yale, B. Paty, P.A. Senior Mbbs, 2018 Clinical Practice Guidelines Hypoglycemia Diabetes Canada Clinical Practice Guidelines Expert Committee, Diabetes.Ca. (2018). https:\/\/doi.org\/10.1016\/j.jcjd.2017.10.010.","DOI":"10.1016\/j.jcjd.2017.10.010"},{"key":"10.1016\/j.addr.2022.114280_b0095","doi-asserted-by":"crossref","unstructured":"Epidemiology of severe hypoglycemia in the diabetes control and complications trial. The DCCT Research Group., Am. J. Med. 90 (1991) 450\u20139. http:\/\/www.ncbi.nlm.nih.gov\/pubmed\/2012085 (accessed April 24, 2020).","DOI":"10.1016\/0002-9343(91)80085-Z"},{"key":"10.1016\/j.addr.2022.114280_b0100","doi-asserted-by":"crossref","first-page":"2087","DOI":"10.1210\/jc.2005-2798","article-title":"Nocturnal hypoglycemia in type 1 diabetes: An assessment of preventive bedtime treatments","volume":"91","author":"Raju","year":"2006","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"10.1016\/j.addr.2022.114280_b0105","article-title":"Hypoglycemia Risk Management at the Georgian Diabetic Camp","volume":"2","author":"Koplatadze","year":"2002","journal-title":"Ann. Biomed. Res. Educ."},{"key":"10.1016\/j.addr.2022.114280_b0110","doi-asserted-by":"crossref","first-page":"S137","DOI":"10.2337\/dc18-S013","article-title":"Management of diabetes in pregnancy: Standards of medical care in Diabetesd","volume":"41","author":"American Diabetes Association","year":"2018","journal-title":"Diabetes Care."},{"key":"10.1016\/j.addr.2022.114280_b0115","doi-asserted-by":"crossref","first-page":"413","DOI":"10.4158\/EP15672.GL","article-title":"American association of clinical endocrinologists and American college of endocrinology - Clinical practice guidelines for developing a diabetes mellitus comprehensive care plan","volume":"21","author":"Handelsman","year":"2015","journal-title":"Endocr. Pract."},{"key":"10.1016\/j.addr.2022.114280_b0120","first-page":"1705","article-title":"Diabetic ketoacidosis","volume":"71","author":"Trachtenbarg","year":"2005","journal-title":"Am. Fam. Physician."},{"key":"10.1016\/j.addr.2022.114280_b0125","article-title":"The Diabetes Textbook","author":"Umpierrez","year":"2019","journal-title":"Diabetes Textb."},{"key":"10.1016\/j.addr.2022.114280_b0130","first-page":"1","article-title":"The discovery of insulin in Toronto: beginning a 100 year journey of research and clinical achievement","author":"Fralick","year":"2021","journal-title":"Diabetologia."},{"key":"10.1016\/j.addr.2022.114280_b0135","doi-asserted-by":"crossref","first-page":"814","DOI":"10.1021\/cr068123a","article-title":"Electrochemical glucose biosensors","volume":"108","author":"Wang","year":"2008","journal-title":"Chem. Rev."},{"key":"10.1016\/j.addr.2022.114280_b0140","doi-asserted-by":"crossref","first-page":"1242","DOI":"10.1177\/193229681200600602","article-title":"Overview of fluorescence glucose sensing: A technology with a bright future, in","author":"Klonoff","year":"2012","journal-title":"J. Diabetes Sci. Technol., Diabetes Technology Society"},{"key":"10.1016\/j.addr.2022.114280_b0145","doi-asserted-by":"crossref","unstructured":"Diabetes Technology: Standards of Medical Care in Diabetes-2020, Diabetes Care. 43 (2020) S77\u2013S88. https:\/\/doi.org\/10.2337\/dc20-S007.","DOI":"10.2337\/dc20-S007"},{"key":"10.1016\/j.addr.2022.114280_b0150","unstructured":"Eversense Continuous Glucose Monitoring System - P160048\/S006, (n.d.). https:\/\/www.fda.gov\/medical-devices\/recently-approved-devices\/eversense-continuousglucose-monitoring-system-p160048s006.pdf (accessed December 9, 2019)."},{"key":"10.1016\/j.addr.2022.114280_b0155","unstructured":"FreeStyle Libre, (2016). http:\/\/www.freestylelibre.es\/."},{"key":"10.1016\/j.addr.2022.114280_b0160","unstructured":"FreeStyle Libre 2, (n.d.). https:\/\/www.freestylelibre.us\/system-overview\/freestyle-libre-2.html (accessed June 17, 2020)."},{"key":"10.1016\/j.addr.2022.114280_b0165","unstructured":"FreeStyle Libre 3: World\u2019s Smallest Sensor is Here | Abbott Newsroom, (n.d.). https:\/\/www.abbott.com\/corpnewsroom\/strategy-and-strength\/freeStyle-libre-3-worlds-smallest-sensor-is-here.html (accessed March 10, 2021)."},{"key":"10.1016\/j.addr.2022.114280_b0170","doi-asserted-by":"crossref","first-page":"43","DOI":"10.11648\/j.ajp.20190502.12","article-title":"Parental Satisfaction on Multiple Daily Injections, Insulin Pump and Flexible Multiple Daily Injections Used for Children with Type 1 Diabetes Mellitus","volume":"5","author":"Shee","year":"2019","journal-title":"Am. J. Pediatr."},{"key":"10.1016\/j.addr.2022.114280_b0175","doi-asserted-by":"crossref","first-page":"1231","DOI":"10.1016\/j.mayocp.2016.06.010","article-title":"New Insulin Delivery Recommendations","volume":"91","author":"Frid","year":"2016","journal-title":"Mayo Clin. Proc."},{"key":"10.1016\/j.addr.2022.114280_b0180","doi-asserted-by":"crossref","first-page":"259","DOI":"10.1007\/s13300-018-0561-7","article-title":"Impact of Insulin Injection and Infusion Routines on Lipohypertrophy and Glycemic Control in Children and Adults with Diabetes","volume":"10","author":"Deeb","year":"2019","journal-title":"Diabetes Ther."},{"key":"10.1016\/j.addr.2022.114280_b0185","doi-asserted-by":"crossref","first-page":"954","DOI":"10.1177\/193229681200600429","article-title":"Insulin infusion set: The Achilles heel of continuous subcutaneous insulin infusion","volume":"6","author":"Heinemann","year":"2012","journal-title":"J. Diabetes Sci. Technol."},{"key":"10.1016\/j.addr.2022.114280_b0190","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1002\/pdi.1960150108","article-title":"Factors related to lipohypertrophy in insulin-treated diabetic patients: Role of educational intervention","volume":"15","author":"Saez-de-Ibarra","year":"1998","journal-title":"Pract. Diabetes Int."},{"key":"10.1016\/j.addr.2022.114280_b0195","doi-asserted-by":"crossref","first-page":"1224","DOI":"10.1016\/j.mayocp.2016.06.012","article-title":"Worldwide Injection Technique Questionnaire Study: Injecting Complications and the Role of the Professional","volume":"91","author":"Frid","year":"2016","journal-title":"Mayo Clin. Proc."},{"key":"10.1016\/j.addr.2022.114280_b0200","doi-asserted-by":"crossref","first-page":"483","DOI":"10.1089\/dia.2018.0074","article-title":"Clinical Implications of Lipohypertrophy among People with Type 1 Diabetes in India","volume":"20","author":"Gupta","year":"2018","journal-title":"Diabetes Technol. Ther."},{"key":"10.1016\/j.addr.2022.114280_b0205","first-page":"4609","article-title":"Prevalence, risk factors, and clinical characteristics of lipodystrophy in insulin-treated patients with diabetes: An old problem in a new era of modern insulin, Diabetes","volume":"13","author":"Thewjitcharoen","year":"2020","journal-title":"Metab. Syndr. Obes. Targets Ther."},{"key":"10.1016\/j.addr.2022.114280_b0210","doi-asserted-by":"crossref","first-page":"284","DOI":"10.1016\/j.diabres.2018.02.005","article-title":"Skin complications of insulin injections: A case presentation and a possible explanation of hypoglycaemia","volume":"138","author":"Gentile","year":"2018","journal-title":"Diabetes Res. Clin. Pract."},{"key":"10.1016\/j.addr.2022.114280_b0215","doi-asserted-by":"crossref","first-page":"500","DOI":"10.1177\/1932296819888213","article-title":"Lipohypertrophy Effect on Glycemic Profile in an Adult With Type 1 Diabetes Using Scanned Continuous Glucose Monitoring","volume":"14","author":"Oriot","year":"2020","journal-title":"J. Diabetes Sci. Technol."},{"key":"10.1016\/j.addr.2022.114280_b0220","doi-asserted-by":"crossref","first-page":"741","DOI":"10.1089\/dia.2012.0038","article-title":"The role of comfort and discomfort in insulin therapy","volume":"14","author":"Aronson","year":"2012","journal-title":"Diabetes Technol. Ther."},{"key":"10.1016\/j.addr.2022.114280_b0225","doi-asserted-by":"crossref","first-page":"2986","DOI":"10.1007\/s12325-019-01101-6","article-title":"Subcutaneous Injection of Drugs: Literature Review of Factors Influencing Pain Sensation at the Injection Site","volume":"36","author":"Usach","year":"2019","journal-title":"Adv. Ther."},{"key":"10.1016\/j.addr.2022.114280_b0230","doi-asserted-by":"crossref","DOI":"10.1155\/2020\/8822686","article-title":"Variation of the Penetration Effort in an Artificial Tissue by Hypodermic Needles","volume":"2020","author":"Gon\u00e7alves","year":"2020","journal-title":"J. Healthc. Eng."},{"key":"10.1016\/j.addr.2022.114280_b0235","doi-asserted-by":"crossref","first-page":"S77","DOI":"10.2337\/dc20-S007","article-title":"Diabetes technology: Standards of medical care in diabetes- 2020","volume":"43","author":"American Diabetes Association","year":"2020","journal-title":"Diabetes Care."},{"key":"10.1016\/j.addr.2022.114280_b0240","doi-asserted-by":"crossref","first-page":"727","DOI":"10.1080\/17425247.2016.1232247","article-title":"Challenges and recent advances in the subcutaneous delivery of insulin","volume":"14","author":"Guo","year":"2017","journal-title":"Expert Opin. Drug Deliv."},{"key":"10.1016\/j.addr.2022.114280_b0245","article-title":"A Novel Ultrafine Needle (UN) for Innocuous and Efficient Subcutaneous Insulin Delivery","volume":"27","author":"Li","year":"2017","journal-title":"Adv. Funct. Mater."},{"key":"10.1016\/j.addr.2022.114280_b0250","doi-asserted-by":"crossref","first-page":"516","DOI":"10.1016\/j.pmn.2021.01.007","article-title":"Needle-Related Pain, Affective Reactions, Fear, and Emotional Coping in Children and Adolescents With Type 1 Diabetes: A Cross-Sectional Study","volume":"22","author":"Hanberger","year":"2021","journal-title":"Pain Manag. Nurs."},{"key":"10.1016\/j.addr.2022.114280_b0255","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1136\/ebnurs-2018-103033","article-title":"Nociceptor-stimulating devices can help reduce pain, anxiety and fear in children requiring regular injections","volume":"23","author":"Waite","year":"2020","journal-title":"Evid. Based. Nurs."},{"key":"10.1016\/j.addr.2022.114280_b0260","doi-asserted-by":"crossref","first-page":"e66","DOI":"10.1016\/j.pedn.2018.04.011","article-title":"Efficacy of Non-pharmacological Methods of Pain Management in Children Undergoing Venipuncture in a Pediatric Outpatient Clinic: A Randomized Controlled Trial of Audiovisual Distraction and External Cold and Vibration","volume":"42","author":"Bergomi","year":"2018","journal-title":"J. Pediatr. Nurs."},{"key":"10.1016\/j.addr.2022.114280_b0265","doi-asserted-by":"crossref","first-page":"502","DOI":"10.1016\/j.jen.2019.04.003","article-title":"Using Buzzy, Shotblocker, and Bubble Blowing in a Pediatric Emergency Department to Reduce the Pain and Fear Caused by Intramuscular Injection: A Randomized Controlled Trial","volume":"45","author":"Yilmaz","year":"2019","journal-title":"J. Emerg. Nurs."},{"key":"10.1016\/j.addr.2022.114280_b0270","doi-asserted-by":"crossref","first-page":"486","DOI":"10.4040\/jkan.2019.49.4.486","article-title":"The Effect on Pain of Buzzy\u00ae and ShotBlocker\u00ae during the Administration of Intramuscular Injections to Children: A Randomized Controlled Trial","volume":"49","author":"Sivri Bilgen","year":"2019","journal-title":"J. Korean Acad. Nurs."},{"key":"10.1016\/j.addr.2022.114280_b0275","doi-asserted-by":"crossref","first-page":"341","DOI":"10.1007\/s13300-019-0574-x","article-title":"EADSG Guidelines: Insulin Storage and Optimisation of Injection Technique in Diabetes Management","volume":"10","author":"Bahendeka","year":"2019","journal-title":"Diabetes Ther."},{"key":"10.1016\/j.addr.2022.114280_b0280","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1089\/dia.2019.0374","article-title":"Precision Dosing of Rapid-Acting Insulin Matters","volume":"22","author":"Aanstoot","year":"2020","journal-title":"Diabetes Technol. Ther."},{"key":"10.1016\/j.addr.2022.114280_b0285","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1177\/1757177420948580","article-title":"DropSafe safety pen needle helps to prevent accidental needlesticks after injections: results of a simulated clinical study","volume":"22","author":"Malinowski","year":"2021","journal-title":"J. Infect. Prev."},{"key":"10.1016\/j.addr.2022.114280_b0290","first-page":"1","article-title":"Patient-Reported Preference and Clinical Efficacy of Insulin Pen Devices With Safety Needles in Adolescents and Young Adults With Type 1 Diabetes: A Prospective Study","volume":"13","author":"Al Hayek","year":"2021","journal-title":"Cureus."},{"key":"10.1016\/j.addr.2022.114280_b0295","doi-asserted-by":"crossref","first-page":"2595","DOI":"10.1007\/s13300-020-00913-y","article-title":"Insulin Injection Practices in a Population of Canadians with Diabetes: An Observational Study","volume":"11","author":"Bari","year":"2020","journal-title":"Diabetes Ther."},{"key":"10.1016\/j.addr.2022.114280_b0300","article-title":"Lipohypertrophy Monitoring Study (LIMO): effect of single use of 4 mm pen needles combined with education on injection site rotation on glycaemic control: confirmation of an unpleasant truth","author":"Bochanen","year":"2021","journal-title":"Diabet. Med."},{"key":"10.1016\/j.addr.2022.114280_b0305","first-page":"1","article-title":"Evaluating the User Preference and Level of Insulin Self-Administration Adherence in Young Patients With Type 1 Diabetes: Experience With Two Insulin Pen Needle Lengths","volume":"12","author":"Al Hayek","year":"2020","journal-title":"Cureus."},{"key":"10.1016\/j.addr.2022.114280_b0310","unstructured":"Bensley Gonsalves, Appropriateness of the 6 mm insulin needle length comparing the glycemic control in overweight obese and normal weight patients with type 2 diabetes \u2013 four years observational study, (n.d.). https:\/\/www.endocrine-abstracts.org\/ea\/0070\/abstracts\/audio-eposter-presentations\/diabetes-obesity-metabolism-and-nutrition\/ea0070aep316\/."},{"key":"10.1016\/j.addr.2022.114280_b0315","doi-asserted-by":"crossref","first-page":"583","DOI":"10.14740\/jocmr3894","article-title":"Adherence to Medication, Physical Activity and Diet in Older Adults With Diabetes: Its Association With Cognition, Anxiety and Depression","volume":"11","author":"Mendes","year":"2019","journal-title":"J. Clin. Med. Res."},{"key":"10.1016\/j.addr.2022.114280_b0320","doi-asserted-by":"crossref","first-page":"373","DOI":"10.1007\/s13300-020-00980-1","article-title":"Smart Insulin Pens are Associated with Improved Clinical Outcomes at Lower Cost Versus Standard-of-Care Treatment of Type 1 Diabetes in Sweden: A Cost-Effectiveness Analysis","volume":"12","author":"Jendle","year":"2021","journal-title":"Diabetes Ther."},{"key":"10.1016\/j.addr.2022.114280_b0325","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1089\/dia.2019.0186","article-title":"Examining the Relationship between Pre-and Postprandial Glucose Levels and Insulin Bolus Timing Using Bluetooth-Enabled Insulin Pen Cap Technology and Continuous Glucose Monitoring","volume":"22","author":"Toschi","year":"2020","journal-title":"Diabetes Technol. Ther."},{"key":"10.1016\/j.addr.2022.114280_b0330","doi-asserted-by":"crossref","first-page":"1129","DOI":"10.2337\/dc18-1631","article-title":"Nonadherence to insulin therapy detected by Bluetooth-enabled pen cap is associated with poor glycemic control","volume":"42","author":"Munshi","year":"2019","journal-title":"Diabetes Care."},{"key":"10.1016\/j.addr.2022.114280_b0335","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1111\/dme.13856","article-title":"News and views: A roundup of some new developments in diabetes","volume":"36","author":"O\u2019Neill","year":"2019","journal-title":"Diabet. Med."},{"key":"10.1016\/j.addr.2022.114280_b0340","unstructured":"Lilly collaborates internationally with leading diabetes technology companies to integrate connected insulin pen solutions for people with diabetes, May 2021. (n.d.). https:\/\/investor.lilly.com\/news-releases\/news-release-details\/lilly-collaborates-internationally-leading-diabetes-technology."},{"key":"10.1016\/j.addr.2022.114280_b0345","first-page":"1","author":"Sanofi-Lantus","year":"2012","journal-title":"Insulin Pen"},{"key":"10.1016\/j.addr.2022.114280_b0350","unstructured":"Toujeo Solostar Insulin Pen, (n.d.). https:\/\/www.toujeo.com\/how-to-use-toujeo-insulin."},{"key":"10.1016\/j.addr.2022.114280_b0355","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1016\/j.diabres.2018.12.007","article-title":"Concentrated insulins in current clinical practice","volume":"148","author":"Schloot","year":"2019","journal-title":"Diabetes Res. Clin. Pract."},{"key":"10.1016\/j.addr.2022.114280_b0360","unstructured":"Max Solostar, (n.d.). https:\/\/www.toujeo.com\/how-to-use-toujeo-insulin."},{"key":"10.1016\/j.addr.2022.114280_b0365","unstructured":"Instructions for use - AllStar Pro, (n.d.). http:\/\/products.sanofi.ca\/en\/allstarpro.pdf."},{"key":"10.1016\/j.addr.2022.114280_b0370","unstructured":"P. Krulevitch, R. Wilk, U. Kraft, D. Savage, N. Foley, J. Glencross, D. Shepherd, Z. Sieh, Medical module for drug delivery pen, US patent 2013 \/ 8556865 B2, 2013."},{"key":"10.1016\/j.addr.2022.114280_b0375","unstructured":"Instructions for use - Humalog KwikPen, (n.d.). http:\/\/pi.lilly.com\/us\/humalog-kwikpen-um.pdf."},{"key":"10.1016\/j.addr.2022.114280_b0380","unstructured":"Basaglar Kwikpen, (n.d.). https:\/\/www.basaglar.com\/hcp\/dosing\/kwikpen."},{"key":"10.1016\/j.addr.2022.114280_b0385","unstructured":"Instructions for use - HumaPen Luxura, (n.d.). https:\/\/pi.lilly.com\/us\/HumaPen_Luxura_HD_um.pdf."},{"key":"10.1016\/j.addr.2022.114280_b0390","unstructured":"R. Byerly, R. Perkins, G. Sardo, Reusable medication delivery device with remaining medication determination capability, US patent 2019 \/ 0038843 A1, 2019."},{"key":"10.1016\/j.addr.2022.114280_b0395","unstructured":"Humalog Junior KwikPen, (n.d.) 1\u20139. https:\/\/www.humalog.com\/type-1-diabetes\/humalog-junior-kwikpen\/."},{"key":"10.1016\/j.addr.2022.114280_b0400","unstructured":"FlexTouch, (n.d.). https:\/\/www.rapidactinginsulin.com\/fiasp\/using-fiasp\/delivery-options.html."},{"key":"10.1016\/j.addr.2022.114280_b0405","unstructured":"Levemir Insulin Pen, (n.d.). https:\/\/www.levemir.com\/levemir-flextouch-and-vial.html."},{"key":"10.1016\/j.addr.2022.114280_b0410","unstructured":"Tresiba FlexTouch, (n.d.). https:\/\/www.tresiba.com\/taking-tresiba\/what-to-know.html."},{"key":"10.1016\/j.addr.2022.114280_b0415","unstructured":"NovoPen Echo, (n.d.). https:\/\/www.novonordisk.com\/our-products\/pens-and-needles\/novopen-echo.html (accessed February 21, 2022)."},{"key":"10.1016\/j.addr.2022.114280_b0420","unstructured":"Autopen, (n.d.). https:\/\/www.owenmumford.com\/en\/healthcare-professionals-product\/autopen\/."},{"key":"10.1016\/j.addr.2022.114280_b0425","unstructured":"ServoPen, (n.d.). https:\/\/yds.ypsomed.com\/en\/injection-systems\/pen-injectors\/servopen.html."},{"key":"10.1016\/j.addr.2022.114280_b0430","unstructured":"new InPen, (n.d.). https:\/\/www.medtronicdiabetes.com\/products\/inpen-smart-insulin-pen-system."},{"key":"10.1016\/j.addr.2022.114280_b0435","unstructured":"Esysta BT Pen, (n.d.). https:\/\/www.emperra.com\/en\/esysta-product-system\/pen\/."},{"key":"10.1016\/j.addr.2022.114280_b0440","unstructured":"Pendiq, (n.d.). https:\/\/pendiq.com\/en\/insulin-pen\/."},{"key":"10.1016\/j.addr.2022.114280_b0445","unstructured":"D. Laptev, V. Peterkova, I.D.- reason, undefined 2018, Frequency and reasons for CSII discontinuation in children and young patients with T1DM, Simul-Europe.Com. (n.d.). http:\/\/simul-europe.com\/2018\/attd\/Files\/(laptevdn@ya.ru)laptev_attd_2018.pdf (accessed May 28, 2020)."},{"key":"10.1016\/j.addr.2022.114280_b0450","unstructured":"R.K. Garg, J. V Hennessey, A.O. Malabanan, Handbook of Inpatient, n.d."},{"key":"10.1016\/j.addr.2022.114280_b0455","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1089\/dia.2018.0295","article-title":"Insulin Bolus Administration in Insulin Pump Therapy: Effect of Bolus Delivery Speed on Insulin Absorption from Subcutaneous Tissue","volume":"21","author":"Regittnig","year":"2019","journal-title":"Diabetes Technol. Ther."},{"key":"10.1016\/j.addr.2022.114280_b0460","doi-asserted-by":"crossref","first-page":"165","DOI":"10.1177\/1932296816653142","article-title":"Boluses in Insulin Therapy: A Commentary","volume":"11","author":"Ziegler","year":"2017","journal-title":"J. Diabetes Sci. Technol."},{"key":"10.1016\/j.addr.2022.114280_b0465","doi-asserted-by":"crossref","DOI":"10.1155\/2018\/1205121","article-title":"Factors Affecting the Absorption of Subcutaneously Administered Insulin: Effect on Variability","volume":"2018","author":"Gradel","year":"2018","journal-title":"J. Diabetes Res."},{"key":"10.1016\/j.addr.2022.114280_b0470","doi-asserted-by":"crossref","first-page":"1579","DOI":"10.2337\/dci18-0002","article-title":"Diabetes technology update: Use of insulin pumps and continuous glucose monitoring in the hospital","volume":"41","author":"Umpierrez","year":"2018","journal-title":"Diabetes Care."},{"key":"10.1016\/j.addr.2022.114280_b0475","doi-asserted-by":"crossref","first-page":"377","DOI":"10.1016\/S2213-8587(17)30014-1","article-title":"Exercise management in type 1 diabetes: a consensus statement","volume":"5","author":"Riddell","year":"2017","journal-title":"Lancet Diabetes Endocrinol."},{"key":"10.1016\/j.addr.2022.114280_b0480","doi-asserted-by":"crossref","first-page":"55","DOI":"10.2337\/diaspect.28.1.55","article-title":"Prevention of exercise-associated dysglycemia: A case study-based approach","volume":"28","author":"Zaharieva","year":"2015","journal-title":"Diabetes Spectr."},{"key":"10.1016\/j.addr.2022.114280_b0485","doi-asserted-by":"crossref","first-page":"84","DOI":"10.1089\/dia.2012.0168","article-title":"Insulin Pump Therapy is associated with Less Post-Exercise Hyperglycemia than multiple daily injections: An observational study of physically active type 1 diabetes patients","volume":"15","author":"Yardley","year":"2013","journal-title":"Diabetes Technol. Ther."},{"key":"10.1016\/j.addr.2022.114280_b0490","article-title":"Less Nocturnal Hypoglycemia but Equivalent Time in Range Among Adults with Type 1 Diabetes Using Insulin Pumps Versus Multiple Daily Injections","author":"McAuley","year":"2020","journal-title":"Diabetes Technol. Ther."},{"key":"10.1016\/j.addr.2022.114280_b0495","doi-asserted-by":"crossref","first-page":"E5","DOI":"10.2337\/dc19-1908","article-title":"Dietary patterns of insulin pump and multiple daily injection users during type 1 diabetes pregnancy","volume":"43","author":"Neoh","year":"2020","journal-title":"Diabetes Care."},{"key":"10.1016\/j.addr.2022.114280_b0500","doi-asserted-by":"crossref","first-page":"845","DOI":"10.1007\/s13300-020-00780-7","article-title":"Evaluation of Glycaemic Control, Glucose Variability and Hypoglycaemia on Long-Term Continuous Subcutaneous Infusion vs. Multiple Daily Injections: Observational Study in Pregnancies With Pre-Existing Type 1 Diabetes","volume":"11","author":"Jotic","year":"2020","journal-title":"Diabetes Ther."},{"key":"10.1016\/j.addr.2022.114280_b0505","doi-asserted-by":"crossref","first-page":"1358","DOI":"10.1001\/jama.2017.13994","article-title":"Association of insulin pump therapy vs insulin injection therapy with severe hypoglycemia, ketoacidosis, and glycemic control among children, adolescents, and young adults with type 1 diabetes","volume":"318","author":"Karges","year":"2017","journal-title":"JAMA - J. Am. Med. Assoc."},{"key":"10.1016\/j.addr.2022.114280_b0510","doi-asserted-by":"crossref","unstructured":"A. Jeyam, F.W. Gibb, J.A. Mcknight, B. Kennon, J.E. O\u2019reilly, T.M. Caparrotta, A. H\u00f6hn, S.J. Mcgurnaghan, L.A.K. Blackbourn, S. Hatam, R.J. Mccrimmon, G. Leese, R.S. Lindsay, J. Petrie, J. Chalmers, S. Philip, S.H. Wild, N. Sattar, P.M. Mckeigue, H.M. Colhoun, Marked improvements in glycaemic outcomes following insulin pump therapy initiation in people with type 1 diabetes: a nationwide observational study in Scotland On behalf of the Scottish Diabetes Research Network (SDRN) Epidemiology Group, (2021) 1320\u20131331. http:\/\/apps.who.int\/.","DOI":"10.1007\/s00125-021-05413-7"},{"key":"10.1016\/j.addr.2022.114280_b0515","doi-asserted-by":"crossref","first-page":"973","DOI":"10.1007\/s00592-019-01326-5","article-title":"Continuous subcutaneous insulin infusion vs modern multiple injection regimens in type 1 diabetes: an updated meta-analysis of randomized clinical trials","volume":"56","author":"Pala","year":"2019","journal-title":"Acta Diabetol."},{"key":"10.1016\/j.addr.2022.114280_b0520","doi-asserted-by":"crossref","first-page":"700","DOI":"10.1016\/S2213-8587(17)30217-6","article-title":"Effect of initiating use of an insulin pump in adults with type 1 diabetes using multiple daily insulin injections and continuous glucose monitoring (DIAMOND): a multicentre, randomised controlled trial","volume":"5","author":"Beck","year":"2017","journal-title":"Lancet Diabetes Endocrinol."},{"key":"10.1016\/j.addr.2022.114280_b0525","doi-asserted-by":"crossref","first-page":"409","DOI":"10.1089\/dia.2019.0041","article-title":"Insulin Pump Combined with Flash Glucose Monitoring: A Therapeutic Option to Improve Glycemic Control in Severely Nonadherent Patients with Type 1 Diabetes","volume":"21","author":"Halbron","year":"2019","journal-title":"Diabetes Technol. Ther."},{"key":"10.1016\/j.addr.2022.114280_b0530","doi-asserted-by":"crossref","unstructured":"J. \u0160oupal, L. Petru\u017eelkov´a, G. Grunberger, A. H´askov´a, M. Fleka\u010d, M. Matoulek, O. Mike\u0161, T. Pelcl, J. \u0160krha, E. Horov´a, J. \u0160krha, C.G. Parkin, \u0160. Sva\u010dina, M. P\u0155az\u0144y, Glycemic outcomes in adults with T1D are impacted more by continuous glucose monitoring than by insulin delivery method: 3 years of follow-up from the comisair study, Diabetes Care. 43 (2020) 37\u201343. https:\/\/doi.org\/10.2337\/dc19-0888.","DOI":"10.2337\/dc19-0888"},{"key":"10.1016\/j.addr.2022.114280_b0535","doi-asserted-by":"crossref","first-page":"253","DOI":"10.1177\/1932296816667510","article-title":"Randomized Cross-Over Study Comparing Two Infusion Sets for CSII in Daily Life","volume":"11","author":"Freckmann","year":"2017","journal-title":"J. Diabetes Sci. Technol."},{"key":"10.1016\/j.addr.2022.114280_b0540","doi-asserted-by":"crossref","first-page":"470","DOI":"10.1177\/0145721716642526","article-title":"Improving Patient Experience With Insulin Infusion Sets: Practical Guidelines and Future Directions","volume":"42","author":"Evert","year":"2016","journal-title":"Diabetes Educ."},{"key":"10.1016\/j.addr.2022.114280_b0545","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1089\/dia.2013.0119","article-title":"Randomized trial of infusion set function: Steel versus teflon","volume":"16","author":"Patel","year":"2014","journal-title":"Diabetes Technol. Ther."},{"key":"10.1016\/j.addr.2022.114280_b0550","doi-asserted-by":"crossref","unstructured":"D. Deiss, P. Adolfsson, M. Alkemade-Van Zomeren, G.B. Bolli, G. Charpentier, C. Cobelli, T. Danne, A. Girelli, H. Mueller, C.A. Verderese, E. Renard, Insulin Infusion Set Use: European Perspectives and Recommendations, Diabetes Technol. Ther. 18 (2016) 517\u2013524. https:\/\/doi.org\/10.1089\/dia.2016.07281.sf.","DOI":"10.1089\/dia.2016.07281.sf"},{"key":"10.1016\/j.addr.2022.114280_b0555","doi-asserted-by":"crossref","first-page":"S254","DOI":"10.1089\/dia.2018.0080","article-title":"Preserving Skin Integrity with Chronic Device Use in Diabetes","volume":"20","author":"Messer","year":"2018","journal-title":"Diabetes Technol. Ther."},{"key":"10.1016\/j.addr.2022.114280_b0560","doi-asserted-by":"crossref","first-page":"429","DOI":"10.1089\/dia.2015.0432","article-title":"Duration of Infusion Set Survival in Lipohypertrophy Versus Nonlipohypertrophied Tissue in Patients with Type 1 Diabetes","volume":"18","author":"Karlin","year":"2016","journal-title":"Diabetes Technol. Ther."},{"key":"10.1016\/j.addr.2022.114280_b0565","unstructured":"D. Diaz, A.M. Dinesen, A. Khalf, G. Eisler, C. Loeum, M. Thakur, M.C. Torjman, K.C. Hsu, P.J. Strasma, J.I. Joseph DO, Micro-CT Imaging of an Insulin Bolus Infusion Through Continuous Subcutaneous Insulin Infusion (CSII) Sets in Live Swine: Quantitative Comparison of Distribution Patterns in Tissue Over Eight Days, (n.d.)."},{"key":"10.1016\/j.addr.2022.114280_b0570","doi-asserted-by":"crossref","first-page":"701-P","DOI":"10.2337\/db21-701-P","article-title":"701-P: Feasibility of an Investigational Extended Wear Infusion Set for Insulin Pump Therapy (IPT) in People with Type 1 Diabetes Mellitus","volume":"70","author":"O\u2019Neal","year":"2021","journal-title":"Diabetes."},{"key":"10.1016\/j.addr.2022.114280_b0575","doi-asserted-by":"crossref","first-page":"127-LB","DOI":"10.2337\/db19-127-LB","article-title":"127-LB: Longevity of the Coated ConvaTec Infusion Set with Lantern Technology","volume":"68","author":"Lal","year":"2019","journal-title":"Diabetes."},{"key":"10.1016\/j.addr.2022.114280_b0580","doi-asserted-by":"crossref","unstructured":"J. Ilany, O. Cohen, N. Konvalina, G. Zhang, S.C. Diabetes, 994-P: clinical study of a new extended wear infusion set, Am Diabetes Assoc. (2022). https:\/\/diabetesjournals.org\/diabetes\/article\/69\/Supplement_1\/994-P\/56695 (accessed February 21, 2022).","DOI":"10.2337\/db20-994-P"},{"key":"10.1016\/j.addr.2022.114280_b0585","doi-asserted-by":"crossref","DOI":"10.2337\/db21-100-LB","article-title":"100-lb: infusion set survival and performance during the Medtronic Extended-Wear Infusion Set (EWIS) pivotal trial","volume":"70","author":"Buckingham","year":"2021","journal-title":"Diabetes."},{"key":"10.1016\/j.addr.2022.114280_b0590","doi-asserted-by":"crossref","unstructured":"Bruce Buckingham, Tatiana Marcal, Lance Hoffman, Gianluca Musolino, Laya Ekhlaspour, Gina Zhang, Sarnath Chattaraj, 997-P: Testing a Novel Infusion Set for Extended Wear Duration, Diabetes. 69 (2020) 997-P. https:\/\/doi.org\/10.2337\/DB20-997-P.","DOI":"10.2337\/db20-997-P"},{"key":"10.1016\/j.addr.2022.114280_b0595","doi-asserted-by":"crossref","first-page":"734","DOI":"10.1089\/dia.2019.0445","article-title":"A Prospective Study of Insulin Infusion Set Use for up to 7 Days: Early Replacement Reasons and Impact on Glycemic Control","volume":"22","author":"Waldenmaier","year":"2020","journal-title":"Diabetes Technol. Ther."},{"key":"10.1016\/j.addr.2022.114280_b0600","doi-asserted-by":"crossref","first-page":"631","DOI":"10.1007\/s12325-018-0703-3","article-title":"Clinical Benefits Over Time Associated with Use of V-Go Wearable Insulin Delivery Device in Adult Patients with Diabetes: A Retrospective Analysis","volume":"35","author":"Sutton","year":"2018","journal-title":"Adv. Ther."},{"key":"10.1016\/j.addr.2022.114280_b0605","doi-asserted-by":"crossref","first-page":"70","DOI":"10.36469\/9731","article-title":"A Pragmatic Clinical Trial to Compare the Real-World Effectiveness of V-Go versus Standard Delivery of Insulin in Patients with Advanced Type 2 Diabetes","volume":"6","author":"Cziraky","year":"2019","journal-title":"J. Heal. Econ. Outcomes Res."},{"key":"10.1016\/j.addr.2022.114280_b0610","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1007\/s40801-019-00173-8","article-title":"Effectiveness of V-Go\u00ae for Patients with Type 2 Diabetes in a Real-World Setting: A Prospective Observational Study","volume":"7","author":"Grunberger","year":"2020","journal-title":"Drugs - Real World Outcomes."},{"key":"10.1016\/j.addr.2022.114280_b0615","doi-asserted-by":"crossref","first-page":"283","DOI":"10.2147\/MDER.S265869","article-title":"Multicenter real-world assessment of the effectiveness of v-go wearable insulin delivery device in adult patients with type 2 diabetes (Enable study): A retrospective analysis","volume":"13","author":"Hundal","year":"2020","journal-title":"Med. Devices Evid. Res."},{"key":"10.1016\/j.addr.2022.114280_b0620","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1177\/1932296818786513","article-title":"Patch Pumps for Insulin","volume":"13","author":"Ginsberg","year":"2019","journal-title":"J. Diabetes Sci. Technol."},{"key":"10.1016\/j.addr.2022.114280_b0625","unstructured":"t:sport mini pump, (n.d.). https:\/\/www.tandemdiabetes.com\/about-us\/pipeline."},{"key":"10.1016\/j.addr.2022.114280_b0630","unstructured":"Sheri R. Colberg, The Athlete\u2019s Guide to Diabetes, (n.d.). https:\/\/books.google.it\/books?id=hJSHDwAAQBAJ&lpg=PT8&ots=NcnAWwF6ic&dq=tubing water sport diabetes&lr&pg=PT8#v=snippet&q=tubing&f=false."},{"key":"10.1016\/j.addr.2022.114280_b0635","doi-asserted-by":"crossref","first-page":"257","DOI":"10.1089\/dia.2017.0346","article-title":"Safety and Feasibility of the OmniPod Hybrid Closed-Loop System in Adult, Adolescent, and Pediatric Patients with Type 1 Diabetes Using a Personalized Model Predictive Control Algorithm","volume":"20","author":"Buckingham","year":"2018","journal-title":"Diabetes Technol. Ther."},{"key":"10.1016\/j.addr.2022.114280_b0640","doi-asserted-by":"crossref","first-page":"585","DOI":"10.1089\/dia.2018.0138","article-title":"Performance of the Omnipod Personalized Model Predictive Control Algorithm with Meal Bolus Challenges in Adults with Type 1 Diabetes","volume":"20","author":"Buckingham","year":"2018","journal-title":"Diabetes Technol. Ther."},{"key":"10.1016\/j.addr.2022.114280_b0645","doi-asserted-by":"crossref","first-page":"72","DOI":"10.2337\/cd20-0022","article-title":"Improved Glycemic Control Following Transition to Tubeless Insulin Pump Therapy in Adults With Type 1 Diabetes","volume":"39","author":"Mehta","year":"2021","journal-title":"Clin. Diabetes."},{"key":"10.1016\/j.addr.2022.114280_b0650","doi-asserted-by":"crossref","unstructured":"T. Biester, A. Schwandt, B. Heidtmann, B. Rami-merhar, Declining Frequency of Acute Complications associated with Tubeless Insulin Pump Use\u00a0: Data from 2, 911 Patients in the German \/ Austrian DPV Registry, (2020) 1\u201330. https:\/\/doi.org\/10.1089\/dia.2020.0675.","DOI":"10.1089\/dia.2020.0675"},{"key":"10.1016\/j.addr.2022.114280_b0655","unstructured":"Insulet\u2019s Omnipod\u00ae HorizonTM Hybrid Closed-Loop System Improves Glycemic Control in Patients as Young as Two Years Old with Type 1 Diabetes, (n.d.). https:\/\/www.businesswire.com\/news\/home\/20190609005008\/en\/Insulet\u2019s-Omnipod\u00ae-HorizonTM-Hybrid-Closed-Loop-System-Improves (accessed December 9, 2019)."},{"key":"10.1016\/j.addr.2022.114280_b0660","unstructured":"Prepivotal Omnipod HorizonTM Automated Glucose Control System (Identification No. NCT04176731), (n.d.). https:\/\/clinicaltrials.gov\/ct2\/show\/NCT04176731 (accessed December 9, 2019)."},{"key":"10.1016\/j.addr.2022.114280_b0665","doi-asserted-by":"crossref","unstructured":"B.A. Buckingham, G.P. Forlenza, A.B. Criego, S.A. Brown, B.W. Bode, C.J. Levy, T.T. Ly, 1276-P: First Home Evaluation of the Omnipod Horizon Automated Glucose Control System in Children with Type 1 Diabetes, Diabetes. 69 (2020) 1276-P. https:\/\/doi.org\/10.2337\/DB20-1276-P.","DOI":"10.2337\/db20-1276-P"},{"key":"10.1016\/j.addr.2022.114280_b0670","unstructured":"EOFLOW, (n.d.). http:\/\/www.eoflow.com\/eng\/main\/main.html (accessed January 7, 2020)."},{"key":"10.1016\/j.addr.2022.114280_b0675","unstructured":"EOFlow publishes the final report on its first clinical trial, (n.d.). http:\/\/www.eoflow.com\/eng\/news\/news_010100.html?bmain=view&uid=86."},{"key":"10.1016\/j.addr.2022.114280_b0680","unstructured":"EOPancreas: A Closed Loop Insulin Patch Pump in Development, (n.d.). https:\/\/asweetlife.org\/eopancreas-a-closed-loop-insulin-patch-pump-in-development\/ (accessed January 7, 2020)."},{"key":"10.1016\/j.addr.2022.114280_b0685","unstructured":"EoPancreas: New Diabetes Patch Pump and CGM System in Development, (n.d.). https:\/\/www.healthline.com\/diabetesmine\/eopancreas-patch-pump-and-cgm-closed-loop-system#4 (accessed January 7, 2020)."},{"key":"10.1016\/j.addr.2022.114280_b0690","unstructured":"SFC Fluidics\u00ae Partners with PercuSense and Diabeloop to Improve Diabetes Care \u2014 SFC Fluidics, (n.d.). https:\/\/www.sfc-fluidics.com\/news-1\/2019\/7\/3\/sfc-fluidics-partners-with-percusense-and-diabeloop-to-improve-diabetes-care (accessed April 6, 2021)."},{"key":"10.1016\/j.addr.2022.114280_b0695","article-title":"Inc., Receives FDA Breakthrough Device Designation \u2014 SFC Fluidics","author":"Fluidics","year":"2021","journal-title":"(n.d.)"},{"key":"10.1016\/j.addr.2022.114280_b0700","unstructured":"The Omnipod DASHTM System, (n.d.). https:\/\/www.myomnipod.com\/DASH (accessed December 9, 2019)."},{"key":"10.1016\/j.addr.2022.114280_b0705","unstructured":"Accu-Chek Diabetes Management Apps and Software, (n.d.). https:\/\/www.accu-chek.com\/apps-and-software (accessed December 9, 2019)."},{"key":"10.1016\/j.addr.2022.114280_b0710","unstructured":"FreeStyle Libre, (2016). https:\/\/www.freestyle.abbott\/ca\/en\/products\/libre\/link.html (accessed December 9, 2019)."},{"key":"10.1016\/j.addr.2022.114280_b0715","doi-asserted-by":"crossref","DOI":"10.2196\/diabetes.8039","article-title":"One Drop | Mobile: An Evaluation of Hemoglobin A1c Improvement Linked to App Engagement","volume":"2","author":"Osborn","year":"2017","journal-title":"JMIR Diabetes."},{"key":"10.1016\/j.addr.2022.114280_b0720","unstructured":"One Drop Mobile, (n.d.). https:\/\/onedrop.today\/pages\/mobile-app (accessed December 9, 2019)."},{"key":"10.1016\/j.addr.2022.114280_b0725","unstructured":"Onduo.com, (n.d.). https:\/\/onduo.com\/ (accessed November 27, 2019)."},{"key":"10.1016\/j.addr.2022.114280_b0730","unstructured":"Medtronic and IBM Watson Health: Surfacing new insights together, (n.d.). https:\/\/www.medtronic.com\/content\/dam\/medtronic-com\/transforming-healthcare\/documents\/medtronic-ibm-watson-health-sugariq-diabetes-app_paper_tp_mdt_corpmark.pdf (accessed December 8, 2019)."},{"key":"10.1016\/j.addr.2022.114280_b0735","unstructured":"Sugar.IQTM Diabetes Assistant, (n.d.). https:\/\/www.medtronicdiabetes.com\/products\/sugar.iq-diabetes-assistant (accessed December 9, 2019)."},{"key":"10.1016\/j.addr.2022.114280_b0740","unstructured":"CarelinkTM personal actionable insights, (n.d.). https:\/\/www.medtronic-diabetes.co.uk\/carelink (accessed December 8, 2019)."},{"key":"10.1016\/j.addr.2022.114280_b0745","unstructured":"Home - Glooko, (n.d.). https:\/\/www.glooko.com\/ (accessed December 9, 2019)."},{"key":"10.1016\/j.addr.2022.114280_b0750","unstructured":"Tidepool, (n.d.). https:\/\/www.tidepool.org\/ (accessed December 9, 2019)."},{"key":"10.1016\/j.addr.2022.114280_b0755","unstructured":"Dexcom CLARITY, (n.d.). https:\/\/www.dexcom.com\/clarity (accessed December 9, 2019)."},{"key":"10.1016\/j.addr.2022.114280_b0760","unstructured":"Senseonics Announces CE Mark Approval for Eversense\u00ae XL CGM System \u2013 Senseonics, (n.d.). https:\/\/www.senseonics.com\/investor-relations\/news-releases\/2017\/09-12-2017-213230489 (accessed January 6, 2020)."},{"key":"10.1016\/j.addr.2022.114280_b0765","doi-asserted-by":"crossref","first-page":"63","DOI":"10.2337\/dc16-1525","article-title":"Accuracy and longevity of an implantable continuous glucose sensor in the PRECISE study: A 180-day, prospective, multicenter, pivotal trial","volume":"40","author":"Kropff","year":"2017","journal-title":"Diabetes Care."},{"key":"10.1016\/j.addr.2022.114280_b0770","doi-asserted-by":"crossref","first-page":"84","DOI":"10.1089\/dia.2021.0182","article-title":"Evaluation of Accuracy and Safety of the Next-Generation Up to 180-Day Long-Term Implantable Eversense Continuous Glucose Monitoring System: The PROMISE Study","volume":"24","author":"Garg","year":"2022","journal-title":"Diabetes Technol. Ther."},{"key":"10.1016\/j.addr.2022.114280_b0775","unstructured":"Senseonics Announces FDA Approval of the Eversense\u00ae E3 Continuous Glucose Monitoring System for Use for Up to 6 months; Provides 2022 Business Outlook \u2013 Senseonics, (n.d.). https:\/\/www.senseonics.com\/investor-relations\/news-releases\/2022\/02-11-2022-120033959 (accessed February 18, 2022)."},{"key":"10.1016\/j.addr.2022.114280_b0780","unstructured":"Senseonics - Eversense XL, (n.d.). https:\/\/global.eversensediabetes.com\/ (accessed February 21, 2022)."},{"key":"10.1016\/j.addr.2022.114280_b0785","unstructured":"Eversense E3 Continuous Glucose Monitoring System now FDA approved - The Diabetes Times, (n.d.). https:\/\/diabetestimes.co.uk\/eversense-e3-continuous-glucose-monitoring-system-now-fda-approved\/ (accessed February 21, 2022)."},{"key":"10.1016\/j.addr.2022.114280_b0790","doi-asserted-by":"crossref","unstructured":"FDA authorizes first fully interoperable continuous glucose monitoring system, streamlines review pathway for similar devices, (2018). https:\/\/doi.org\/10.31525\/fda2-ucm602870.htm.","DOI":"10.31525\/fda2-ucm602870.htm"},{"key":"10.1016\/j.addr.2022.114280_b0795","doi-asserted-by":"crossref","first-page":"S21","DOI":"10.1089\/dia.2018.0101","article-title":"Ever-Increasing Insulin-Requiring Patients Globally","volume":"20","author":"Garg","year":"2018","journal-title":"Diabetes Technol. Ther."},{"key":"10.1016\/j.addr.2022.114280_b0800","doi-asserted-by":"crossref","DOI":"10.1155\/2019\/4684815","article-title":"Utility of real-time and retrospective continuous glucose monitoring in patients with type 2 diabetes mellitus: A meta-analysis of randomized controlled trials","volume":"2019","author":"Ida","year":"2019","journal-title":"J. Diabetes Res."},{"key":"10.1016\/j.addr.2022.114280_b0805","unstructured":"T. Kompala, A. Neinstein, A new era: increasing continuous glucose monitoring use in type 2 diabetes, Am. J. Manag. Care. 25 (2019) SP123\u2013SP126."},{"key":"10.1016\/j.addr.2022.114280_b0810","unstructured":"B. Levine, A. Brown, What\u2019s Coming from Dexcom in 2020? A Low-Cost, Slimmer, Fully Disposable CGM | diaTribe, (2018). https:\/\/diatribe.org\/whats-coming-dexcom-2020-low-cost-slimmer-fully-disposable-cgm (accessed December 9, 2019)."},{"key":"10.1016\/j.addr.2022.114280_b0815","first-page":"55","article-title":"Flash Glucose-Sensing Technology as a Replacement for Blood Glucose Monitoring for the Management of Insulin-Treated Type 2 Diabetes: a Multicenter","volume":"8","author":"Haak","year":"2017","journal-title":"Open-Label Randomized Controlled Trial, Diabetes Ther."},{"key":"10.1016\/j.addr.2022.114280_b0820","unstructured":"Abbott\u2032s FreeStyle secures CE Mark for Use in Europe, (2018). https:\/\/abbott.mediaroom.com\/2018-10-01-Abbott-s-FreeStyle-R-Libre-2-with-Optional-Real-Time-Alarms-Secures-CE-Mark-for-Use-in-Europe (accessed March 26, 2020)."},{"key":"10.1016\/j.addr.2022.114280_b0825","article-title":"Accuracy of a 14-Day Factory-Calibrated Continuous Glucose Monitoring System With Advanced Algorithm in Pediatric and Adult Population With Diabetes","author":"Alva","year":"2020","journal-title":"J. Diabetes Sci. Technol."},{"key":"10.1016\/j.addr.2022.114280_b0830","unstructured":"MiniMed Insulin Pump Therapy, (n.d.). https:\/\/www.medtronicdiabetes.com\/home (accessed December 9, 2019)."},{"key":"10.1016\/j.addr.2022.114280_b0835","unstructured":"Hot New Technology from Medtronic Diabetes, (n.d.). https:\/\/www.healthline.com\/diabetesmine\/medtronic-diabetes-technology#future-products (accessed March 10, 2021)."},{"key":"10.1016\/j.addr.2022.114280_b0845","unstructured":"Eversense Smart Transmitter, (n.d.). https:\/\/global.eversensediabetes.com\/products\/eversense-smart-transmitter (accessed January 6, 2020)."},{"key":"10.1016\/j.addr.2022.114280_b0850","doi-asserted-by":"crossref","first-page":"338","DOI":"10.1016\/S0019-9958(65)90241-X","article-title":"Fuzzy sets","volume":"8","author":"Zadeh","year":"1965","journal-title":"Inf. Control."},{"key":"10.1016\/j.addr.2022.114280_b0855","doi-asserted-by":"crossref","first-page":"303","DOI":"10.1177\/1932296817710475","article-title":"Artificial Intelligence Methodologies and Their Application to Diabetes","volume":"12","author":"Rigla","year":"2018","journal-title":"J. Diabetes Sci. Technol."},{"key":"10.1016\/j.addr.2022.114280_b0860","doi-asserted-by":"crossref","first-page":"1910","DOI":"10.2337\/diacare.28.8.1910","article-title":"Acute psychological stress affects glucose concentrations in patients with type 1 diabetes following food intake but not in the fasting state","volume":"28","author":"Wiesli","year":"2005","journal-title":"Diabetes Care."},{"key":"10.1016\/j.addr.2022.114280_b0865","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1080\/23328940.2015.1131506","article-title":"Body temperature regulation in diabetes","volume":"3","author":"Kenny","year":"2016","journal-title":"Temperature."},{"key":"10.1016\/j.addr.2022.114280_b0870","doi-asserted-by":"crossref","first-page":"525","DOI":"10.1177\/1932296815582222","article-title":"\u201csnap-n-Eat\u201d: Food recognition and nutrition estimation on a smartphone","volume":"9","author":"Zhang","year":"2015","journal-title":"J. Diabetes Sci. Technol."},{"key":"10.1016\/j.addr.2022.114280_b0875","doi-asserted-by":"crossref","first-page":"S216","DOI":"10.1089\/dia.2018.0091","article-title":"The Hybrid Closed-Loop System: Evolution and Practical Applications","volume":"20","author":"Weaver","year":"2018","journal-title":"Diabetes Technol. Ther."},{"key":"10.1016\/j.addr.2022.114280_b0880","doi-asserted-by":"crossref","first-page":"789","DOI":"10.2337\/dc17-1682","article-title":"Optimizing hybrid closed-loop therapy in adolescents and emerging adults using the mini med 670G system","volume":"41","author":"Messer","year":"2018","journal-title":"Diabetes Care."},{"key":"10.1016\/j.addr.2022.114280_b0885","unstructured":"M.H.Q. Kayani, K.N. Malik, S. Ahmad, A. Khaqan, S. Shuja, Qadeer-Ul-Hasan, S.A. Malik, R.A. Riaz, A switching based PID technique for blood glucose control, Biomed. Res. 28 (2017) 8477\u20138483. https:\/\/www.alliedacademies.org\/articles\/a-switching-based-pid-technique-for-blood-glucose-control-8643.html (accessed November 27, 2019)."},{"key":"10.1016\/j.addr.2022.114280_b0890","first-page":"503","article-title":"Overnight glucose control in people with type 1 diabetes, Biomed. Signal Process","volume":"39","author":"Boiroux","year":"2018","journal-title":"Control."},{"key":"10.1016\/j.addr.2022.114280_b0895","first-page":"904","article-title":"Simultaneous model predictive control and moving horizon estimation for blood glucose regulation in Type 1 diabetes, Optim. Control Appl","volume":"39","author":"Copp","year":"2018","journal-title":"Methods."},{"key":"10.1016\/j.addr.2022.114280_b0900","doi-asserted-by":"crossref","unstructured":"D. Boiroux, A.K. Duun-Henriksen, S. Schmidt, K. N\u00f8rgaard, S. Madsbad, O. Skyggebjerg, P.R. Jensen, N.K. Poulsen, H. Madsen, J.B. J\u00f8rgensen, Overnight control of blood glucose in people with type 1 diabetes, in: IFAC Proc. Vol., IFAC Secretariat, 2012: pp. 73\u201378. https:\/\/doi.org\/10.3182\/20120829-3-HU-2029.00106.","DOI":"10.3182\/20120829-3-HU-2029.00106"},{"key":"10.1016\/j.addr.2022.114280_b0905","doi-asserted-by":"crossref","first-page":"237","DOI":"10.1016\/j.automatica.2016.04.015","article-title":"Periodic zone-MPC with asymmetric costs for outpatient-ready safety of an artificial pancreas to treat type 1 diabetes","volume":"71","author":"Gondhalekar","year":"2016","journal-title":"Automatica."},{"key":"10.1016\/j.addr.2022.114280_b0910","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1016\/j.artmed.2017.09.007","article-title":"Temporal case-based reasoning for type 1 diabetes mellitus bolus insulin decision support","volume":"85","author":"Brown","year":"2018","journal-title":"Artif. Intell. Med."},{"key":"10.1016\/j.addr.2022.114280_b0915","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1109\/JBHI.2015.2464088","article-title":"An advanced bolus calculator for type 1 diabetes: System architecture and usability results","volume":"20","author":"Pes","year":"2016","journal-title":"IEEE J. Biomed. Heal. Informatics."},{"key":"10.1016\/j.addr.2022.114280_b0920","doi-asserted-by":"crossref","unstructured":"P. Herrero, M. El-Sharkawy, J. Daniels, N. Jugnee, C.N. Uduku, M. Reddy, N. Oliver, P. Georgiou, The Bio-inspired Artificial Pancreas for Type 1 Diabetes Control in the Home: System Architecture and Preliminary Results:, Https:\/\/Doi.Org\/10.1177\/1932296819881456. 13 (2019) 1017\u20131025. https:\/\/doi.org\/10.1177\/1932296819881456.","DOI":"10.1177\/1932296819881456"},{"key":"10.1016\/j.addr.2022.114280_b0925","unstructured":"FDA approves first automated insulin delivery device for type 1 diabetes, (n.d.). https:\/\/www.fda.gov\/news-events\/press-announcements\/fda-approves-first-automated-insulin-delivery-device-type-1-diabetes (accessed February 21, 2022)."},{"key":"10.1016\/j.addr.2022.114280_b0930","unstructured":"Medtronic Secures CE Mark for MiniMedTM 780G Advanced Hybrid Closed Loop System Designed to Further Simplify Type 1 Diabetes Management | Medtronic, (n.d.). https:\/\/www.diabetes.ie\/medtronic-secures-ce-mark-for-minimed-780g-advanced-hybrid-closed-loop-system-designed-to-further-simplify-type-1-diabetes-management\/ (accessed February 21, 2022)."},{"key":"10.1016\/j.addr.2022.114280_b0935","unstructured":"Tandem Diabetes Care Announces FDA Clearance of the t:slim X2 Insulin Pump with Control-IQ Advanced Hybrid Closed-Loop Technology, (n.d.). http:\/\/investor.tandemdiabetes.com\/news-releases\/news-release-details\/tandem-diabetes-care-announces-fda-clearance-tslim-x2-insulin (accessed January 6, 2020)."},{"key":"10.1016\/j.addr.2022.114280_b0940","unstructured":"Cambridge-Developed CamAPS FX AID Smartphone App Receives CE-Mark, Launches in UK | Close Concerns Knowledgebase, (n.d.). https:\/\/www.closeconcerns.com\/knowledgebase\/r\/f7127cb0 (accessed March 10, 2021)."},{"key":"10.1016\/j.addr.2022.114280_b0945","unstructured":"Diabeloop obtains CE marking and launches new round of funding, (2018). https:\/\/www.diabeloop.com\/media-press\/press-releases\/diabeloop-obtains-ce-marking-and-launches-new-round-of-funding-2 (accessed April 23, 2020)."},{"key":"10.1016\/j.addr.2022.114280_b0950","doi-asserted-by":"crossref","first-page":"911","DOI":"10.1007\/s40265-014-0226-4","article-title":"The evolution of insulin glargine and its continuing contribution to diabetes care","volume":"74","author":"Hilgenfeld","year":"2014","journal-title":"Drugs."},{"key":"10.1016\/j.addr.2022.114280_b0955","first-page":"33","article-title":"Closed-loop technology: a practical guide, Pract","volume":"38","author":"Hartnell","year":"2021","journal-title":"Diabetes."},{"key":"10.1016\/j.addr.2022.114280_b0960","unstructured":"Observational Study of the Use of DBLG1 System in Real Life (Identification No.NCT04749693), (n.d.). https:\/\/clinicaltrials.gov\/ct2\/show\/NCT04749693 (accessed March 10, 2021)."},{"key":"10.1016\/j.addr.2022.114280_b0965","doi-asserted-by":"crossref","first-page":"e2","DOI":"10.1016\/S2589-7500(19)30007-X","article-title":"Closed-loop insulin delivery systems for patients with diabetes","volume":"1","author":"Garg","year":"2019","journal-title":"Lancet Digit. Heal."},{"key":"10.1016\/j.addr.2022.114280_b0970","doi-asserted-by":"crossref","first-page":"e17","DOI":"10.1016\/S2589-7500(19)30003-2","article-title":"Closed-loop insulin delivery in adults with type 1 diabetes in real-life conditions: a 12-week multicentre, open-label randomised controlled crossover trial","volume":"1","author":"Benhamou","year":"2019","journal-title":"Lancet Digit. Heal."},{"key":"10.1016\/j.addr.2022.114280_b0975","unstructured":"About Kaleido, (n.d.). https:\/\/www.hellokaleido.com\/en\/about-kaleido#scroll-to-15 (accessed March 26, 2020)."},{"key":"10.1016\/j.addr.2022.114280_b0980","unstructured":"DBLG1TM System: features and components, (n.d.). https:\/\/www.dbl-diabetes.com\/dblg1-system\/features (accessed March 26, 2020)."},{"key":"10.1016\/j.addr.2022.114280_b0985","doi-asserted-by":"crossref","first-page":"549","DOI":"10.1007\/s00592-018-1123-1","article-title":"Customization of home closed-loop insulin delivery in adult patients with type 1 diabetes, assisted with structured remote monitoring: the pilot WP7 Diabeloop study","volume":"55","author":"Benhamou","year":"2018","journal-title":"Acta Diabetol."},{"key":"10.1016\/j.addr.2022.114280_b0990","unstructured":"World\u2019s first artificial pancreas app licensed for people with type 1 diabetes - JDRF, the type 1 diabetes charity, (n.d.). https:\/\/jdrf.org.uk\/news\/worlds-first-artificial-pancreas-app-licensed-for-people-with-type-1-diabetes-in-the-uk\/ (accessed March 24, 2020)."},{"key":"10.1016\/j.addr.2022.114280_b0995","unstructured":"CamAPS\u00ae FX | Advanced Therapeutics (UK) Ltd, (n.d.). https:\/\/advancedtherapeutics.org.uk\/camaps-fx\/ (accessed March 24, 2020)."},{"key":"10.1016\/j.addr.2022.114280_b1000","doi-asserted-by":"crossref","first-page":"644","DOI":"10.1056\/NEJMoa1602494","article-title":"Closed-Loop insulin delivery during pregnancy in women with type 1 diabetes","volume":"375","author":"Stewart","year":"2016","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.addr.2022.114280_b1005","doi-asserted-by":"crossref","first-page":"1321","DOI":"10.1016\/S0140-6736(18)31947-0","article-title":"Closed-loop insulin delivery in suboptimally controlled type 1 diabetes: a multicentre, 12-week randomised trial","volume":"392","author":"Tauschmann","year":"2018","journal-title":"Lancet."},{"key":"10.1016\/j.addr.2022.114280_b1010","doi-asserted-by":"crossref","first-page":"1080","DOI":"10.1177\/1932296817702656","article-title":"Closing the Loop in Adults, Children and Adolescents With Suboptimally Controlled Type 1 Diabetes Under Free Living Conditions: A Psychosocial Substudy","volume":"11","author":"Barnard","year":"2017","journal-title":"J. Diabetes Sci. Technol."},{"key":"10.1016\/j.addr.2022.114280_b1015","doi-asserted-by":"crossref","first-page":"2129","DOI":"10.1056\/NEJMoa1509351","article-title":"Home use of an artificial beta cell in type 1 diabetes","volume":"373","author":"Thabit","year":"2015","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.addr.2022.114280_b1020","year":"2019","journal-title":"Case Med. Res."},{"key":"10.1016\/j.addr.2022.114280_b1025","unstructured":"FDA interoperable automated glycemic controller, (n.d.). https:\/\/www.accessdata.fda.gov\/scripts\/cdrh\/cfdocs\/cfpcd\/classification.cfm?id=694 (accessed March 10, 2021)."},{"key":"10.1016\/j.addr.2022.114280_b1030","unstructured":"FDA authorizes first interoperable, automated insulin dosing controller designed to allow more choices for patients looking to customize their individual diabetes management device system | FDA, (n.d.). https:\/\/www.fda.gov\/news-events\/press-announcements\/fda-authorizes-first-interoperable-automated-insulin-dosing-controller-designed-allow-more-choices (accessed March 10, 2021)."},{"key":"10.1016\/j.addr.2022.114280_b1035","unstructured":"Tidepool, (n.d.). https:\/\/www.tidepool.org\/blog\/tidepool-delivering-loop (accessed December 8, 2019)."},{"key":"10.1016\/j.addr.2022.114280_b1040","unstructured":"About our FDA submission of Tidepool Loop | Tidepool blog, (n.d.). https:\/\/www.tidepool.org\/blog\/99-years-closer-about-our-fda-submission-of-tidepool-loop (accessed March 10, 2021)."},{"key":"10.1016\/j.addr.2022.114280_b1045","unstructured":"Artificial pancreas app for type 1 diabetes patients launched after University of Cambridge research, (n.d.). https:\/\/www.cambridgeindependent.co.uk\/news\/artificial-pancreas-app-for-type-1-diabetes-patients-launched-after-university-of-cambridge-research-9102950\/ (accessed March 26, 2020)."},{"key":"10.1016\/j.addr.2022.114280_b1050","doi-asserted-by":"crossref","first-page":"1707","DOI":"10.1056\/NEJMoa1907863","article-title":"Six-month randomized, multicenter trial of closed-loop control in type 1 diabetes","volume":"381","author":"Brown","year":"2019","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.addr.2022.114280_b1055","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1089\/dia.2016.0421","article-title":"Glucose Outcomes with the In-Home Use of a Hybrid Closed-Loop Insulin Delivery System in Adolescents and Adults with Type 1 Diabetes","volume":"19","author":"Garg","year":"2017","journal-title":"Diabetes Technol. Ther."},{"key":"10.1016\/j.addr.2022.114280_b1060","doi-asserted-by":"crossref","unstructured":"S.H. Duffus, Z. Al Ta\u2019ani, J.C. Slaughter, K.D. Niswender, J.M. Gregory, Increased proportion of time in hybrid closed-loop \u201cAuto Mode\u201d is associated with improved glycaemic control for adolescent and young patients with adult type 1 diabetes using the MiniMed 670G insulin pump, Diabetes, Obes. Metab. 22 (2020) 688\u2013693. https:\/\/doi.org\/10.1111\/dom.13912.","DOI":"10.1111\/dom.13912"},{"key":"10.1016\/j.addr.2022.114280_b1065","article-title":"OR14-5 Challenges in implementing Hybrid Closed Loop Insulin Pump Therapy (medtronic 670g) In A \u201cReal World\u201d","volume":"3","author":"Goodwin","year":"2019","journal-title":"Clinical Setting., J. Endocr. Soc."},{"key":"10.1016\/j.addr.2022.114280_b1070","doi-asserted-by":"crossref","first-page":"321","DOI":"10.1089\/dia.2019.0302","article-title":"Switching from Suspend-Before-Low Insulin Pump Technology to a Hybrid Closed-Loop System Improves Glucose Control and Reduces Glucose Variability: A Retrospective Observational Case-Control Study","volume":"22","author":"Lepore","year":"2020","journal-title":"Diabetes Technol. Ther."},{"key":"10.1016\/j.addr.2022.114280_b1075","first-page":"759","article-title":"Closed loop control in adolescents and children during winter sports: Use of the Tandem Control-IQ AP system, Pediatr","volume":"20","author":"Ekhlaspour","year":"2019","journal-title":"Diabetes."},{"key":"10.1016\/j.addr.2022.114280_b1080","doi-asserted-by":"crossref","first-page":"507","DOI":"10.4155\/tde-2020-0055","article-title":"Review of the Omnipod\u00ae 5 Automated Glucose Control System Powered by HorizonTM for the treatment of Type 1 diabetes","volume":"11","author":"Cobry","year":"2020","journal-title":"Ther. Deliv."},{"key":"10.1016\/j.addr.2022.114280_b1085","unstructured":"New Prediction Feature for Hypoglycemia Now Available in Sugar.IQ(TM) Personal Diabetes Assistant App, Developed by Medtronic and IBM Watson Health, (n.d.). https:\/\/news.medtronic.com\/2019-01-03-New-Prediction-Feature-for-Hypoglycemia-Now-Available-in-Sugar-IQ-TM-Personal-Diabetes-Assistant-App-Developed-by-Medtronic-and-IBM-Watson-Health (accessed February 21, 2022)."},{"key":"10.1016\/j.addr.2022.114280_b1090","article-title":"Pivotal Trial Data for MiniMedTM 780G Advanced Hybrid Closed Loop System with Automated Correction Bolus Feature","author":"Medtronic Presents","year":"2022","journal-title":"(n.d.)"},{"key":"10.1016\/j.addr.2022.114280_b1095","first-page":"dc202250","article-title":"Improved Glycemic Outcomes With Medtronic MiniMed Advanced Hybrid Closed-Loop Delivery: Results From a Randomized Crossover Trial Comparing Automated Insulin Delivery With Predictive Low Glucose Suspend in People With Type 1 Diabetes","author":"Collyns","year":"2021","journal-title":"Diabetes Care."},{"key":"10.1016\/j.addr.2022.114280_b1100","unstructured":"Control-IQ Technology, (n.d.). https:\/\/www.tandemdiabetes.com\/providers\/products\/control-iq (accessed March 26, 2020)."},{"key":"10.1016\/j.addr.2022.114280_b1105","doi-asserted-by":"crossref","first-page":"1471","DOI":"10.1038\/s41591-021-01453-z","article-title":"Fully automated closed-loop glucose control compared with standard insulin therapy in adults with type 2 diabetes requiring dialysis: an open-label, randomized crossover trial","volume":"27","author":"Boughton","year":"2021","journal-title":"Nat. Med."},{"key":"10.1016\/j.addr.2022.114280_b1110","unstructured":"Closed-loop in Adults With T2D Requiring Dialysis (Identification No. NCT04025775), (n.d.). https:\/\/clinicaltrials.gov\/ct2\/show\/NCT04025775 (accessed September 3, 2021)."},{"key":"10.1016\/j.addr.2022.114280_b1115","unstructured":"Closed-loop in Adults With T2D Not Requiring Dialysis (Identification No. NCT04701424), (n.d.). https:\/\/clinicaltrials.gov\/ct2\/show\/NCT04701424 (accessed September 3, 2021)."},{"key":"10.1016\/j.addr.2022.114280_b1120","doi-asserted-by":"crossref","first-page":"217","DOI":"10.1016\/j.mayocp.2017.12.003","article-title":"The Role of Glucagon in the Pathophysiology and Treatment of Type 2 Diabetes","volume":"93","author":"H\u00e6dersdal","year":"2018","journal-title":"Mayo Clin. Proc."},{"key":"10.1016\/j.addr.2022.114280_b1125","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1111\/dom.12789","article-title":"Glucagon in artificial pancreas systems: Potential benefits and safety profile of future chronic use, Diabetes","volume":"19","author":"Taleb","year":"2017","journal-title":"Obes. Metab."},{"key":"10.1016\/j.addr.2022.114280_b1130","doi-asserted-by":"crossref","first-page":"215","DOI":"10.2337\/ds18-0097","article-title":"Insulin-and-glucagon artificial pancreas versus insulin-alone artificial pancreas: A short review","volume":"32","author":"Haidar","year":"2019","journal-title":"Diabetes Spectr."},{"key":"10.1016\/j.addr.2022.114280_b1135","doi-asserted-by":"crossref","first-page":"179","DOI":"10.1016\/j.ecl.2019.10.008","article-title":"Role of Glucagon in Automated Insulin Delivery","volume":"49","author":"Wilson","year":"2020","journal-title":"Endocrinol. Metab. Clin. North Am."},{"key":"10.1016\/j.addr.2022.114280_b1140","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1126\/scitranslmed.3000619","article-title":"Bi-hormonal closed-loop glucose control for type 1 diabetes","volume":"2","author":"El-Khatib","year":"2010","journal-title":"Sci. Transl. Med."},{"key":"10.1016\/j.addr.2022.114280_b1145","doi-asserted-by":"crossref","first-page":"214","DOI":"10.1210\/jc.2015-3003","article-title":"Single- and dual-hormone artificial pancreas for overnight glucose control in type 1 diabetes","volume":"101","author":"Haidar","year":"2016","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"10.1016\/j.addr.2022.114280_b1150","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1016\/S2213-8587(14)70226-8","article-title":"Comparison of dual-hormone artificial pancreas, single-hormone artificial pancreas, and conventional insulin pump therapy for glycaemic control in patients with type 1 diabetes: An open-label randomised controlled crossover trial","volume":"3","author":"Haidar","year":"2015","journal-title":"Lancet Diabetes Endocrinol."},{"key":"10.1016\/j.addr.2022.114280_b1155","doi-asserted-by":"crossref","first-page":"2561","DOI":"10.1007\/s00125-016-4107-0","article-title":"Efficacy of single-hormone and dual-hormone artificial pancreas during continuous and interval exercise in adult patients with type 1 diabetes: randomised controlled crossover trial","volume":"59","author":"Taleb","year":"2016","journal-title":"Diabetologia."},{"key":"10.1016\/j.addr.2022.114280_b1160","doi-asserted-by":"crossref","first-page":"847","DOI":"10.1177\/1932296818757795","article-title":"Stable Liquid Glucagon: Beyond Emergency Hypoglycemia Rescue","volume":"12","author":"Wilson","year":"2018","journal-title":"J. Diabetes Sci. Technol."},{"key":"10.1016\/j.addr.2022.114280_b1165","doi-asserted-by":"crossref","first-page":"531","DOI":"10.2337\/dc17-1402","article-title":"Pharmacokinetic and pharmacodynamic characteristics of dasiglucagon, a novel soluble and stable glucagon analog","volume":"41","author":"H\u00f6velmann","year":"2018","journal-title":"Diabetes Care."},{"key":"10.1016\/j.addr.2022.114280_b1170","unstructured":"Beta Bionics Receives FDA Breakthrough Device Designation for the iLetTM Bionic Pancreas System, (n.d.). https:\/\/www.globenewswire.com\/news-release\/2019\/12\/10\/1958317\/0\/en\/Beta-Bionics-Receives-FDA-Breakthrough-Device-Designation-for-the-iLet-Bionic-Pancreas-System.html (accessed January 6, 2020)."},{"key":"10.1016\/j.addr.2022.114280_b1175","doi-asserted-by":"crossref","first-page":"e118","DOI":"10.2337\/dc20-1086","article-title":"Performance of the insulin-only ilet bionic pancreas and the bihormonal ilet using dasiglucagon in adults with type 1 diabetes in a home-use setting","volume":"44","author":"Castellanos","year":"2021","journal-title":"Diabetes Care."},{"key":"10.1016\/j.addr.2022.114280_b1180","doi-asserted-by":"crossref","first-page":"198-OR","DOI":"10.2337\/db20-198-OR","article-title":"198-OR: Individual Response of Automated Glycemic Control with the iLet Bionic Pancreas in the Insulin-Only vs. Bihormonal Configuration with the Stable Glucagon Analog Dasiglucagon","volume":"69","author":"Sherwood","year":"2020","journal-title":"Diabetes."},{"key":"10.1016\/j.addr.2022.114280_b1185","doi-asserted-by":"crossref","unstructured":"L. Wilson, P. Jacobs, N. Resalat, R. Reddy, J. El Youssef, D. Branigan, J. Leitschuh, B. Senf, V. GABO, J. Castle, 1038-P: Results of Interim Analysis of a Randomized Crossover Study in Type 1 Diabetes (T1D) of a Dual-Hormone Closed-Loop System with XerisolTM Glucagon vs. Insulin-Only Closed-Loop System vs. a Predictive Low Glucose Suspend System, Diabetes. 68 (2019) 1038-P. https:\/\/doi.org\/10.2337\/db19-1038-P.","DOI":"10.2337\/db19-1038-P"},{"key":"10.1016\/j.addr.2022.114280_b1190","doi-asserted-by":"crossref","first-page":"944","DOI":"10.2174\/1389203720666190328111833","article-title":"Human Amylin: From Pathology to Physiology and Pharmacology","volume":"20","author":"Ling","year":"2019","journal-title":"Curr. Protein Pept. Sci."},{"key":"10.1016\/j.addr.2022.114280_b1195","doi-asserted-by":"crossref","first-page":"621","DOI":"10.1016\/j.ijpharm.2018.06.039","article-title":"Physico-chemical properties of co-formulated fast-acting insulin with pramlintide","volume":"547","author":"da Silva","year":"2018","journal-title":"Int. J. Pharm."},{"key":"10.1016\/j.addr.2022.114280_b1200","doi-asserted-by":"crossref","unstructured":"G. Ryan, T.A. Briscoe, L. Jobe, Review of pramlintide as adjunctive therapy in treatment of type 1 and type 2 diabetes, (2008) 203\u2013214.","DOI":"10.2147\/DDDT.S3225"},{"key":"10.1016\/j.addr.2022.114280_b1205","doi-asserted-by":"crossref","first-page":"597","DOI":"10.2337\/dc19-1922","article-title":"A novel dual-hormone insulin- and-pramlintide artificial pancreas for type 1 diabetes: A randomized controlled crossover trial","volume":"43","author":"Haidar","year":"2020","journal-title":"Diabetes Care."},{"key":"10.1016\/j.addr.2022.114280_b1210","doi-asserted-by":"crossref","first-page":"2090","DOI":"10.1111\/dom.14447","article-title":"Alleviating carbohydrate counting with a FiASP-plus-pramlintide closed-loop delivery system (artificial pancreas): Feasibility and pilot studies, Diabetes","volume":"23","author":"Tsoukas","year":"2021","journal-title":"Obes. Metab."},{"key":"10.1016\/j.addr.2022.114280_b1215","unstructured":"Adocia, Compositions in the form of an injectable aqueous solution including at least human insulin A21G and a glucagon suppressor with prandial action, n.d. https:\/\/patents.justia.com\/patent\/10610572."},{"key":"10.1016\/j.addr.2022.114280_b1220","doi-asserted-by":"crossref","first-page":"961","DOI":"10.1111\/dom.14302","article-title":"ADO09, a co-formulation of the amylin analogue pramlintide and the insulin analogue A21G, lowers postprandial blood glucose versus insulin lispro in type 1 diabetes, Diabetes","volume":"23","author":"Andersen","year":"2021","journal-title":"Obes. Metab."},{"key":"10.1016\/j.addr.2022.114280_b1225","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1002\/advs.202101575","article-title":"Ultra-Fast Insulin-Pramlintide Co-Formulation for Improved Glucose Management in Diabetic Rats","volume":"8","author":"Maikawa","year":"2021","journal-title":"Adv. Sci."},{"key":"10.1016\/j.addr.2022.114280_b1230","article-title":"Stimuli responsive polymeric nanocarriers for drug delivery applications: Volume 2: Advanced nanocarriers for therapeutics","author":"Makhlouf","year":"2018","journal-title":"Elsevier"},{"key":"10.1016\/j.addr.2022.114280_b1235","unstructured":"Smart Insulin\/Glucose Responsive Insulin Market, (n.d.). https:\/\/www.alliedmarketresearch.com\/Smart-insulin-market (accessed November 27, 2019)."},{"key":"10.1016\/j.addr.2022.114280_b1240","doi-asserted-by":"crossref","first-page":"231","DOI":"10.1016\/j.jconrel.2017.01.043","article-title":"Glucose-responsive insulin release: Analysis of mechanisms, formulations, and evaluation criteria","volume":"263","author":"Yang","year":"2017","journal-title":"J. Control. Release."},{"key":"10.1016\/j.addr.2022.114280_b1245","doi-asserted-by":"crossref","first-page":"1068","DOI":"10.1177\/193229681100500507","article-title":"Review of glucose oxidases and glucose dehydrogenases: A bird\u2019s eye view of glucose sensing enzymes","volume":"5","author":"Ferri","year":"2011","journal-title":"J. Diabetes Sci. Technol."},{"key":"10.1016\/j.addr.2022.114280_b1250","doi-asserted-by":"crossref","first-page":"8260","DOI":"10.1073\/pnas.1505405112","article-title":"Microneedle-array patches loaded with hypoxia-sensitive vesicles provide fast glucose-responsive insulin delivery","volume":"112","author":"Yu","year":"2015","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"10.1016\/j.addr.2022.114280_b1255","doi-asserted-by":"crossref","first-page":"5457","DOI":"10.1166\/jnn.2016.11655","article-title":"Glucose-responsive micelles for controlled insulin release based on transformation from amphiphilic to double hydrophilic","volume":"16","author":"Li","year":"2016","journal-title":"J. Nanosci. Nanotechnol."},{"key":"10.1016\/j.addr.2022.114280_b1260","doi-asserted-by":"crossref","first-page":"8733","DOI":"10.1016\/j.biomaterials.2012.08.041","article-title":"Super long-term glycemic control in diabetic rats by glucose-sensitive LbL films constructed of supramolecular insulin assembly","volume":"33","author":"Luo","year":"2012","journal-title":"Biomaterials."},{"key":"10.1016\/j.addr.2022.114280_b1265","doi-asserted-by":"crossref","first-page":"9459","DOI":"10.1039\/c1cc12740c","article-title":"A glucose-responsive controlled release of insulin system based on enzyme multilayers-coated mesoporous silica particles","volume":"47","author":"Zhao","year":"2011","journal-title":"Chem. Commun."},{"key":"10.1016\/j.addr.2022.114280_b1270","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1002\/adfm.201001762","article-title":"Nanotechnology-enabled closed loop insulin delivery device: In vitro and in vivo evaluation of glucose-regulated insulin release for diabetes control","volume":"21","author":"Gordijo","year":"2011","journal-title":"Adv. Funct. Mater."},{"key":"10.1016\/j.addr.2022.114280_b1275","doi-asserted-by":"crossref","first-page":"3975","DOI":"10.1016\/S0032-3861(99)00620-5","article-title":"Preparation and dynamic response of cationic copolymer hydrogels containing glucose oxidase","volume":"41","author":"Podual","year":"2000","journal-title":"Polymer (Guildf)."},{"key":"10.1016\/j.addr.2022.114280_b1280","doi-asserted-by":"crossref","first-page":"3578","DOI":"10.1002\/aic.14108","article-title":"Insulin release dynamics from poly(diethylaminoethyl methacrylate) hydrogel systems","volume":"59","author":"Marek","year":"2013","journal-title":"AIChE J."},{"key":"10.1016\/j.addr.2022.114280_b1285","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1016\/j.jconrel.2004.02.026","article-title":"Control of pore size and permeability of a glucose-responsive gating membrane for insulin delivery","volume":"97","author":"Chu","year":"2004","journal-title":"J. Control. Release."},{"key":"10.1016\/j.addr.2022.114280_b1290","doi-asserted-by":"crossref","first-page":"3495","DOI":"10.1021\/bm500364a","article-title":"Bio-inspired synthetic nanovesicles for glucose-responsive release of insulin","volume":"15","author":"Tai","year":"2014","journal-title":"Biomacromolecules."},{"key":"10.1016\/j.addr.2022.114280_b1295","doi-asserted-by":"crossref","first-page":"733","DOI":"10.1021\/acs.nanolett.6b03848","article-title":"Hypoxia and H2O2 Dual-Sensitive Vesicles for Enhanced Glucose-Responsive Insulin Delivery","volume":"17","author":"Yu","year":"2017","journal-title":"Nano Lett."},{"key":"10.1016\/j.addr.2022.114280_b1300","doi-asserted-by":"crossref","DOI":"10.1126\/sciadv.aaq0723","article-title":"Synthetic \u201csmart gel\u201d provides glucose-responsive insulin delivery in diabetic mice","volume":"3","author":"Matsumoto","year":"2017","journal-title":"Sci. Adv."},{"key":"10.1016\/j.addr.2022.114280_b1305","doi-asserted-by":"crossref","DOI":"10.1002\/adma.201901051","article-title":"Glucose-Responsive Composite Microneedle Patch for Hypoglycemia-Triggered Delivery of Native Glucagon","volume":"31","author":"GhavamiNejad","year":"2019","journal-title":"Adv. Mater."},{"key":"10.1016\/j.addr.2022.114280_b1310","doi-asserted-by":"crossref","first-page":"29512","DOI":"10.1073\/pnas.2011099117","article-title":"Dual self-regulated delivery of insulin and glucagon by a hybrid patch","volume":"117","author":"Wang","year":"2020","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"10.1016\/j.addr.2022.114280_b1315","doi-asserted-by":"crossref","first-page":"1137","DOI":"10.1016\/j.ijbiomac.2011.09.014","article-title":"Glucose and pH dual-responsive concanavalin A based microhydrogels for insulin delivery","volume":"49","author":"Yin","year":"2011","journal-title":"Int. J. Biol. Macromol."},{"key":"10.1016\/j.addr.2022.114280_b1320","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1016\/S0168-3659(01)00447-3","article-title":"Modulated insulin delivery from glucose-sensitive hydrogel dosage forms","volume":"77","author":"Kim","year":"2001","journal-title":"J. Control. Release."},{"key":"10.1016\/j.addr.2022.114280_b1325","doi-asserted-by":"crossref","first-page":"724","DOI":"10.1016\/j.ijbiomac.2018.11.261","article-title":"Concanavalin A-sugar affinity based system: Binding interactions, principle of glucose-responsiveness, and modulated insulin release for diabetes care","volume":"124","author":"Yin","year":"2019","journal-title":"Int. J. Biol. Macromol."},{"key":"10.1016\/j.addr.2022.114280_b1330","doi-asserted-by":"crossref","first-page":"11205","DOI":"10.1016\/j.tet.2004.08.051","article-title":"The relationship among pK a, pH, and binding constants in the interactions between boronic acids and diols - It is not as simple as it appears","volume":"60","author":"Yan","year":"2004","journal-title":"Tetrahedron."},{"key":"10.1016\/j.addr.2022.114280_b1335","doi-asserted-by":"crossref","first-page":"2124","DOI":"10.1002\/anie.201106252","article-title":"A synthetic approach toward a self-regulated insulin delivery system","volume":"51","author":"Matsumoto","year":"2012","journal-title":"Angew. Chemie - Int. Ed."},{"key":"10.1016\/j.addr.2022.114280_b1340","doi-asserted-by":"crossref","first-page":"eaaw4357","DOI":"10.1126\/sciadv.aaw4357","article-title":"Charge-switchable polymeric complex for glucose-responsive insulin delivery in mice and pigs","volume":"5","author":"Wang","year":"2019","journal-title":"Sci. Adv."},{"key":"10.1016\/j.addr.2022.114280_b1345","doi-asserted-by":"crossref","first-page":"260","DOI":"10.1097\/CRD.0000000000000266","article-title":"Long-Acting Basal Insulins","volume":"27","author":"Gallegos Aragon","year":"2019","journal-title":"Cardiol. Rev."},{"key":"10.1016\/j.addr.2022.114280_b1350","doi-asserted-by":"crossref","first-page":"6158","DOI":"10.1021\/ja051038k","article-title":"Reversible insulin self-assembly under carbohydrate control","volume":"127","author":"Hoeg-Jensen","year":"2005","journal-title":"J. Am. Chem. Soc."},{"key":"10.1016\/j.addr.2022.114280_b1355","doi-asserted-by":"crossref","first-page":"2401","DOI":"10.1073\/pnas.1424684112","article-title":"Glucose-responsive insulin activity by covalent modification with aliphatic phenylboronic acid conjugates","volume":"112","author":"Chou","year":"2015","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"10.1016\/j.addr.2022.114280_b1360","doi-asserted-by":"crossref","first-page":"8032","DOI":"10.1039\/c3cs60148j","article-title":"Selective sensing of saccharides using simple boronic acids and their aggregates","volume":"42","author":"Wu","year":"2013","journal-title":"Chem. Soc. Rev."},{"key":"10.1016\/j.addr.2022.114280_b1365","doi-asserted-by":"crossref","first-page":"52","DOI":"10.1038\/s41557-018-0155-z","article-title":"A biomimetic receptor for glucose","volume":"11","author":"Tromans","year":"2019","journal-title":"Nat. Chem."},{"key":"10.1016\/j.addr.2022.114280_b1370","doi-asserted-by":"crossref","first-page":"299","DOI":"10.2337\/db17-0577","article-title":"Engineering glucose responsiveness into insulin","volume":"67","author":"Kaarsholm","year":"2018","journal-title":"Diabetes."},{"key":"10.1016\/j.addr.2022.114280_b1375","doi-asserted-by":"crossref","first-page":"1173","DOI":"10.2337\/db18-0099","article-title":"Superior glycemic control with a glucose-Responsive insulin analog: Hepatic and nonhepatic impacts","volume":"67","author":"Moore","year":"2018","journal-title":"Diabetes."},{"key":"10.1016\/j.addr.2022.114280_b1380","doi-asserted-by":"crossref","first-page":"417","DOI":"10.1002\/cpt.1215","article-title":"Clinical Evaluation of MK-2640: An Insulin Analog With Glucose-Responsive Properties","volume":"105","author":"Krug","year":"2019","journal-title":"Clin. Pharmacol. Ther."},{"key":"10.1016\/j.addr.2022.114280_b1385","doi-asserted-by":"crossref","unstructured":"M.A. Jarosinski, B. Dhayalan, N. Rege, D. Chatterjee, M.A. Weiss, \u2018Smart\u2019 insulin-delivery technologies and intrinsic glucose-responsive insulin analogues, Diabetol. 2021 645. 64 (2021) 1016\u20131029. https:\/\/doi.org\/10.1007\/S00125-021-05422-6.","DOI":"10.1007\/s00125-021-05422-6"},{"key":"10.1016\/j.addr.2022.114280_b1390","article-title":"Insulin analogues with a glucose-regulated conformational switch","author":"Weiss","year":"2016","journal-title":"US10584156B2"},{"key":"10.1016\/j.addr.2022.114280_b1395","doi-asserted-by":"crossref","unstructured":"G. Scapin, V.P. Dandey, Z. Zhang, W. Prosise, A. Hruza, T. Kelly, T. Mayhood, C. Strickland, C.S. Potter, B. Carragher, Structure of the insulin receptor\u2013insulin complex by single-particle cryo-EM analysis, Nat. 2018 5567699. 556 (2018) 122\u2013125. https:\/\/doi.org\/10.1038\/nature26153.","DOI":"10.1038\/nature26153"},{"key":"10.1016\/j.addr.2022.114280_b1400","doi-asserted-by":"crossref","first-page":"1829","DOI":"10.1021\/acschembio.9b00420","article-title":"A Disulfide Scan of Insulin by [3 + 1] Methodology Exhibits Site-Specific Influence on Bioactivity","volume":"14","author":"Brunel","year":"2019","journal-title":"ACS Chem. Biol."},{"key":"10.1016\/j.addr.2022.114280_b1405","doi-asserted-by":"crossref","first-page":"12046","DOI":"10.1073\/pnas.1512465112","article-title":"Zwitterionic gel encapsulation promotes protein stability, enhances pharmacokinetics, and reduces immunogenicity","volume":"112","author":"Zhang","year":"2015","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"10.1016\/j.addr.2022.114280_b1410","doi-asserted-by":"crossref","first-page":"10167","DOI":"10.1039\/C9NR01687B","article-title":"Glucose regulation by modified boronic acid-sulfobetaine zwitterionic nanogels-a non-hormonal strategy for the potential treatment of hyperglycemia","volume":"11","author":"Ghavaminejad","year":"2019","journal-title":"Nanoscale."},{"key":"10.1016\/j.addr.2022.114280_b1415","doi-asserted-by":"crossref","DOI":"10.1002\/smll.201603028","article-title":"Insulin-Responsive Glucagon Delivery for Prevention of Hypoglycemia","volume":"13","author":"Yu","year":"2017","journal-title":"Small."},{"key":"10.1016\/j.addr.2022.114280_b1420","unstructured":"K. Regier, Emily. Wolf, Alexander. Close, Getting to Glucose Responsive Insulin \u2013 How \u201cSmart\u201d Will It Be?, (2016). https:\/\/diatribe.org\/getting-glucose-responsive-insulin-how-smart-will-it-be?fbclid=IwAR2XB4gnvhfc0RWP4mjXlgxdm7Wm3X95IziIlWbQxhuwgOU2dmu5zTIIXqw (accessed December 16, 2019)."},{"key":"10.1016\/j.addr.2022.114280_b1425","doi-asserted-by":"crossref","first-page":"2533","DOI":"10.1039\/c2lc40139h","article-title":"In vitro and in vivo testing of glucose-responsive insulin-delivery microdevices in diabetic rats","volume":"12","author":"Chu","year":"2012","journal-title":"Lab Chip."},{"key":"10.1016\/j.addr.2022.114280_b1430","doi-asserted-by":"crossref","first-page":"5580","DOI":"10.1002\/anie.201300958","article-title":"Glucose- and pH-Responsive Controlled Release of Cargo from Protein-Gated Carbohydrate-Functionalized Mesoporous Silica Nanocontainers","volume":"52","author":"Wu","year":"2013","journal-title":"Angew. Chemie Int. Ed."},{"key":"10.1016\/j.addr.2022.114280_b1435","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1007\/s11095-020-02918-5","article-title":"Stimuli-Responsive Insulin Delivery Devices","volume":"37","author":"Fuchs","year":"2020","journal-title":"Pharm. Res."},{"key":"10.1016\/j.addr.2022.114280_b1440","doi-asserted-by":"crossref","first-page":"2140","DOI":"10.1021\/ja510147n","article-title":"Stimuli-Responsive Nanomaterials for Biomedical Applications","volume":"137","author":"Blum","year":"2015","journal-title":"J. Am. Chem. Soc."},{"key":"10.1016\/j.addr.2022.114280_b1445","doi-asserted-by":"crossref","first-page":"1902004","DOI":"10.1002\/adma.201902004","article-title":"Glucose-Responsive Insulin and Delivery Systems: Innovation and Translation","volume":"32","author":"Wang","year":"2020","journal-title":"Adv. Mater."},{"key":"10.1016\/j.addr.2022.114280_b1450","doi-asserted-by":"crossref","DOI":"10.1002\/advs.201600124","article-title":"Reactive-Oxygen-Species-Responsive Drug Delivery Systems: Promises and Challenges","volume":"4","author":"Saravanakumar","year":"2017","journal-title":"Adv. Sci."},{"key":"10.1016\/j.addr.2022.114280_b1455","doi-asserted-by":"crossref","first-page":"225","DOI":"10.1111\/j.1476-5381.1946.tb00041.x","article-title":"Some pharmacological and chemotherapeutic properties of notatin","volume":"1","author":"Broom","year":"1946","journal-title":"Br. J. Pharmacol. Chemother."},{"key":"10.1016\/j.addr.2022.114280_b1460","doi-asserted-by":"crossref","first-page":"227","DOI":"10.1128\/jb.32.2.227-237.1936","article-title":"Identification of Hemagglutinin of Jack Bean with Concanavalin A","volume":"32","author":"Sumner","year":"1936","journal-title":"J. Bacteriol."},{"key":"10.1016\/j.addr.2022.114280_b1465","first-page":"1","article-title":"Glucose-responsive insulin patch for the regulation of blood glucose in mice and minipigs","author":"Yu","year":"2020","journal-title":"Nat. Biomed. Eng."},{"key":"10.1016\/j.addr.2022.114280_b1470","doi-asserted-by":"crossref","unstructured":"M. Wu, Y. Zhang, H. Huang, J. Li, H. Liu, Z. Guo, L. Xue, S. Liu, Y. Lei, Assisted 3D printing of microneedle patches for minimally invasive glucose control in diabetes, (2020). https:\/\/doi.org\/10.1016\/j.msec.2020.111299.","DOI":"10.1016\/j.msec.2020.111299"},{"key":"10.1016\/j.addr.2022.114280_b1475","doi-asserted-by":"crossref","first-page":"1539","DOI":"10.1007\/s12274-018-2264-9","article-title":"Glucose-responsive oral insulin delivery for postprandial glycemic regulation","volume":"12","author":"Yu","year":"2019","journal-title":"Nano Res."},{"key":"10.1016\/j.addr.2022.114280_b1480","doi-asserted-by":"crossref","first-page":"96","DOI":"10.1186\/s12951-020-00652-z","article-title":"Oral delivery of insulin with intelligent glucose-responsive switch for blood glucose regulation","volume":"18","author":"Zhou","year":"2020","journal-title":"J Nanobiotechnol."},{"key":"10.1016\/j.addr.2022.114280_b1485","doi-asserted-by":"crossref","unstructured":"A. Abramson, E. Caffarel-Salvador, M. Khang, D. Dellal, D. Silverstein, Y. Gao, M.R. Frederiksen, A. Vegge, F. Hub\u00e1lek, J.J. Water, A. V. Friderichsen, J. Fels, R.K. Kirk, C. Cleveland, J. Collins, S. Tamang, A. Hayward, T. Landh, S.T. Buckley, N. Roxhed, U. Rahbek, R. Langer, G. Traverso, An ingestible self-orienting system for oral delivery of macromolecules, Science (80-.). 363 (2019) 611\u2013615. https:\/\/doi.org\/10.1126\/science.aau2277.","DOI":"10.1126\/science.aau2277"},{"key":"10.1016\/j.addr.2022.114280_b1490","doi-asserted-by":"crossref","first-page":"1512","DOI":"10.1038\/s41591-019-0598-9","article-title":"A luminal unfolding microneedle injector for oral delivery of macromolecules","volume":"25","author":"Abramson","year":"2019","journal-title":"Nat. Med."},{"key":"10.1016\/j.addr.2022.114280_b1495","doi-asserted-by":"crossref","first-page":"1275","DOI":"10.1016\/j.clinthera.2014.06.025","article-title":"Inhaled insulin: A breath of fresh air? a review of inhaled insulin","volume":"36","author":"Santos Cavaiola","year":"2014","journal-title":"Clin. Ther."},{"key":"10.1016\/j.addr.2022.114280_b1500","unstructured":"FDA, Drug Approval Package: Exubera (insulin human [rDNA origin] inhalation powder) NDA #021868, (2006). https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/nda\/2006\/021868_exubera_toc.cfm (accessed April 24, 2020)."},{"key":"10.1016\/j.addr.2022.114280_b1505","doi-asserted-by":"crossref","first-page":"518","DOI":"10.1177\/193229680800200325","article-title":"The failure of exubera: Are we beating a dead horse?","volume":"2","author":"Heinemann","year":"2008","journal-title":"J. Diabetes Sci. Technol."},{"key":"10.1016\/j.addr.2022.114280_b1510","unstructured":"T. Goldberg, E. Wong, Afrezza (Insulin Human) Inhalation Powder, 40 (2015) 735\u2013741. https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/nda\/2014\/022472Orig1s000TOC.cfm (accessed April 24, 2020)."},{"key":"10.1016\/j.addr.2022.114280_b1515","doi-asserted-by":"crossref","first-page":"639","DOI":"10.1089\/dia.2018.0200","article-title":"Improved postprandial glucose with inhaled technosphere insulin compared with insulin aspart in patients with type 1 diabetes on multiple daily injections: The STAT study","volume":"20","author":"Akturk","year":"2018","journal-title":"Diabetes Technol. Ther."},{"key":"10.1016\/j.addr.2022.114280_b1520","first-page":"735","article-title":"Afrezza (Insulin Human) Inhalation Powder: A New Inhaled Insulin for the Management Of Type-1 or Type-2 Diabetes Mellitus","volume":"40","author":"Goldberg","year":"2015","journal-title":"P T."},{"key":"10.1016\/j.addr.2022.114280_b1525","doi-asserted-by":"crossref","first-page":"180","DOI":"10.2337\/diaspect.29.3.180","article-title":"Commentary: Why was inhaled insulin a failure in the market?","volume":"29","author":"Oleck","year":"2016","journal-title":"Diabetes Spectr."},{"key":"10.1016\/j.addr.2022.114280_b1530","doi-asserted-by":"crossref","first-page":"1274","DOI":"10.1016\/S0140-6736(19)31334-0","article-title":"Advances in \u03b2-cell replacement therapy for the treatment of type 1 diabetes","volume":"394","author":"Vantyghem","year":"2019","journal-title":"Lancet."},{"key":"10.1016\/j.addr.2022.114280_b1535","doi-asserted-by":"crossref","first-page":"230","DOI":"10.1056\/NEJM200007273430401","article-title":"Islet transplantation in seven patients with type 1 diabetes mellitus using a glucocorticoid-free immunosuppressive regimen","volume":"343","author":"Shapiro","year":"2000","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.addr.2022.114280_b1540","doi-asserted-by":"crossref","first-page":"1318","DOI":"10.1056\/NEJMoa061267","article-title":"International trial of the Edmonton protocol for islet transplantation","volume":"355","author":"Shapiro","year":"2006","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.addr.2022.114280_b1545","doi-asserted-by":"crossref","first-page":"2060","DOI":"10.2337\/diabetes.54.7.2060","article-title":"Five-year follow-up after clinical islet transplantation","volume":"54","author":"Ryan","year":"2005","journal-title":"Diabetes."},{"key":"10.1016\/j.addr.2022.114280_b1550","first-page":"833","volume":"51","author":"Qi","year":"2016","journal-title":"Five-year follow-up of patients with type 1 diabetes transplanted with allogeneic islets: the UIC experience"},{"key":"10.1016\/j.addr.2022.114280_b1555","doi-asserted-by":"crossref","first-page":"268","DOI":"10.1038\/nrendo.2016.178","article-title":"Clinical pancreatic islet transplantation","volume":"13","author":"Shapiro","year":"2017","journal-title":"Nat. Rev. Endocrinol."},{"key":"10.1016\/j.addr.2022.114280_b1560","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1111\/j.1399-0012.2011.01411.x","article-title":"A health economic analysis of clinical islet transplantation","volume":"26","author":"Beckwith","year":"2012","journal-title":"Clin. Transplant."},{"key":"10.1016\/j.addr.2022.114280_b1565","volume":"NCT02854696)","year":"2020","journal-title":"(Identification No."},{"key":"10.1016\/j.addr.2022.114280_b1570","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1136\/bmjopen-2016-013434","article-title":"Randomised, prospective, medico-economic nationwide French study of islet transplantation in patients with severely unstable type 1 diabetes: The STABILOT study protocol","volume":"7","author":"Lablanche","year":"2017","journal-title":"BMJ Open."},{"key":"10.1016\/j.addr.2022.114280_b1575","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1900\/RDS.2017.14.51","article-title":"Encapsulated islet transplantation: Where do we stand?","volume":"14","author":"Vaithilingam","year":"2017","journal-title":"Rev. Diabet. Stud."},{"key":"10.1016\/j.addr.2022.114280_b1580","doi-asserted-by":"crossref","first-page":"370","DOI":"10.1097\/MAT.0000000000001252","article-title":"The Current Status of Bioartificial Pancreas Devices","author":"Photiadis","year":"2021","journal-title":"ASAIO J."},{"key":"10.1016\/j.addr.2022.114280_b1585","doi-asserted-by":"crossref","first-page":"1","DOI":"10.3727\/000000007783464461","article-title":"Factors influencing the loss of \u03b2-cell mass in islet transplantation","volume":"16","author":"Emamaullee","year":"2007","journal-title":"Cell Transplant."},{"issue":"Suppl","key":"10.1016\/j.addr.2022.114280_b1590","first-page":"2001","article-title":"Diabetes. Islet cell transplantation","volume":"358","author":"Shapiro","year":"2001","journal-title":"Lancet."},{"key":"10.1016\/j.addr.2022.114280_b1595","unstructured":"B. Cooper-Jones, C. Ford, Islet cell replacement therapy for insulin-dependent diabetes, CADTH. (2017)."},{"key":"10.1016\/j.addr.2022.114280_b1600","doi-asserted-by":"crossref","first-page":"338","DOI":"10.1038\/nrd.2016.232","article-title":"Advances in islet encapsulation technologies","volume":"16","author":"Desai","year":"2017","journal-title":"Nat. Rev. Drug Discov."},{"key":"10.1016\/j.addr.2022.114280_b1605","unstructured":"ViaCyte Announces $27 Million Financing to Advance Next Generation Cell Therapies for Diabetes - ViaCyte, (n.d.). https:\/\/viacyte.com\/press-releases\/viacyte-announces-27-million-financing-to-advance-next-generation-cell-therapies-for-diabetes\/ (accessed June 22, 2020)."},{"key":"10.1016\/j.addr.2022.114280_b1610","unstructured":"ViaCyte Announces Initiation of Phase 2 Study of Encapsulated Cell Therapy for Type 1 Diabetes Patients - ViaCyte, (n.d.). https:\/\/viacyte.com\/press-releases\/viacyte-announces-initiation-of-phase-2-study-of-encapsulated-cell-ther-apy-for-type-1-diabetes-patients\/ (accessed March 3, 2021)."},{"key":"10.1016\/j.addr.2022.114280_b1615","unstructured":"A Safety and Tolerability Study of VC-02TM Combination Product in Subjects With Type 1 Diabetes Mellitus (Identification No. NCT03162926), (n.d.). https:\/\/clinicaltrials.gov\/ct2\/show\/record\/NCT03162926?term=viacyte&draw=2&rank=2."},{"key":"10.1016\/j.addr.2022.114280_b1620","unstructured":"A Safety, Tolerability, and Efficacy Study of VC-02TM Combination Product in Subjects With Type 1 Diabetes Mellitus and Hypoglycemia Unawareness (Identification No. NCT03163511), (n.d.). https:\/\/clinicaltrials.gov\/ct2\/show\/record\/NCT03163511?term=viacyte&draw=2&rank=1."},{"key":"10.1016\/j.addr.2022.114280_b1625","doi-asserted-by":"crossref","first-page":"196-LB","DOI":"10.2337\/db21-196-LB","article-title":"196-LB: Stem Cell-Derived Islet Replacement Therapy (VC-02) Demonstrates Production of C-Peptide in Patients with Type 1 Diabetes (T1D) and Hypoglycemia Unawareness","volume":"70","author":"Keymeulen","year":"2021","journal-title":"Diabetes."},{"key":"10.1016\/j.addr.2022.114280_b1630","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/s13287-018-1099-3","article-title":"Generation of pancreatic \u03b2 cells for treatment of diabetes: Advances and challenges","volume":"9","author":"Shahjalal","year":"2018","journal-title":"Stem Cell Res. Ther."},{"key":"10.1016\/j.addr.2022.114280_b1635","first-page":"1","article-title":"Biotechs Race to Develop Stem Cell Treatments for","author":"Bender","year":"2019","journal-title":"Diabetes"},{"key":"10.1016\/j.addr.2022.114280_b1640","unstructured":"C. Thanos, D. Lavin, B. Bintz, D. Bhatnagar, J. Mills, M. Billings, Cell Housing Device, International patent WO 2019\/068059 Al, 2019."},{"key":"10.1016\/j.addr.2022.114280_b1645","unstructured":"Top Companies Developing Cell Therapy Treatments For Diabetes, (n.d.). https:\/\/bioinformant.com\/stem-cells-for-diabetes\/ (accessed June 27, 2020)."},{"key":"10.1016\/j.addr.2022.114280_b1650","unstructured":"Semma Therapeutics Announces Pre-Clinical Proof-Of-Concept In Two Lead Programs In Type 1 Diabetes, (2019). https:\/\/www.biospace.com\/article\/releases\/semma-therapeutics-announces-pre-clinical-proof-of-concept-in-two-lead-programs-in-type-1-diabetes\/ (accessed December 20, 2019)."},{"key":"10.1016\/j.addr.2022.114280_b1655","unstructured":"Vertex Announces FDA Fast Track Designation and Initiation of a Phase 1\/2 Clinical Trial for VX-880, a Novel Investigational Cell Therapy for the Treatment of Type 1 Diabetes, (2021). www.vrtx.com. (accessed August 25, 2021)."},{"key":"10.1016\/j.addr.2022.114280_b1660","unstructured":"Vertex Announces Positive Day 90 Data for the First Patient in the Phase 1\/2 Clinical Trial Dosed With VX-880, a Novel Investigational Stem Cell-Derived Therapy for the Treatment of Type 1 Diabetes, (2021). https:\/\/www.businesswire.com\/news\/home\/20211018005226\/en\/ (accessed October 25, 2021)."},{"key":"10.1016\/j.addr.2022.114280_b1665","unstructured":"SERAXIS Inc. publishes clinical trial considerations for a type 1 diabetes stem cell-derived therapy, (2018). https:\/\/www.prnewswire.com\/news-releases\/seraxis-inc-publishes-clinical-trial-considerations-for-a-type-1-diabetes-stem-cell-derived-therapy-300747501.html."},{"key":"10.1016\/j.addr.2022.114280_b1670","unstructured":"Seraxis Islet Technology Aims for Practical T1D Cure | Insulin Nation, (n.d.). https:\/\/insulinnation.com\/research\/seraxis-islet-technology-aims-for-practical-t1d-cure\/ (accessed July 16, 2020)."},{"key":"10.1016\/j.addr.2022.114280_b1675","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.aax9106","article-title":"Gene-edited human stem cell\u2013derived \u03b2 cells from a patient with monogenic diabetes reverse preexisting diabetes in mice","volume":"12","author":"Maxwell","year":"2020","journal-title":"Sci. Transl. Med."},{"key":"10.1016\/j.addr.2022.114280_b1680","doi-asserted-by":"crossref","first-page":"92","DOI":"10.1016\/j.addr.2018.04.018","article-title":"Cell encapsulation: Overcoming barriers in cell transplantation in diabetes and beyond","volume":"139","author":"Farina","year":"2019","journal-title":"Adv. Drug Deliv. Rev."},{"key":"10.1016\/j.addr.2022.114280_b1685","doi-asserted-by":"crossref","first-page":"134","DOI":"10.3389\/fbioe.2019.00134","article-title":"Polymeric approaches to reduce tissue responses against devices applied for islet-cell encapsulation","volume":"7","author":"Hu","year":"2019","journal-title":"Front. Bioeng. Biotechnol."},{"key":"10.1016\/j.addr.2022.114280_b1690","first-page":"E263","article-title":"Designing a retrievable and scalable cell encapsulation device for potential treatment of type 1 diabetes","volume":"115","author":"An","year":"2017","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"10.1016\/j.addr.2022.114280_b1695","doi-asserted-by":"crossref","first-page":"1381","DOI":"10.1002\/bit.25895","article-title":"Progress and challenges in macroencapsulation approaches for type 1 diabetes (T1D) treatment: Cells, biomaterials, and devices","volume":"113","author":"Song","year":"2016","journal-title":"Biotechnol. Bioeng."},{"key":"10.1016\/j.addr.2022.114280_b1700","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1016\/j.addr.2013.07.018","article-title":"Encapsulated islets for diabetes therapy: History, current progress, and critical issues requiring solution","volume":"67\u201368","author":"Scharp","year":"2014","journal-title":"Adv. Drug Deliv. Rev."},{"key":"10.1016\/j.addr.2022.114280_b1705","doi-asserted-by":"crossref","first-page":"11481","DOI":"10.1021\/acsomega.9b01272","article-title":"Sustained Release of Vascular Endothelial Growth Factor from Poly(\u03b5-caprolactone-PEG-\u03b5-caprolactone)-b-Poly(L-lactide) Multiblock Copolymer Microspheres","volume":"4","author":"Scheiner","year":"2019","journal-title":"ACS Omega."},{"key":"10.1016\/j.addr.2022.114280_b1710","doi-asserted-by":"crossref","first-page":"2294","DOI":"10.1097\/TP.0000000000000864","article-title":"Diabetes is reversed in a murine model by marginal mass syngeneic islet transplantation using a subcutaneous cell pouch device","volume":"99","author":"Pepper","year":"2015","journal-title":"Transplantation."},{"key":"10.1016\/j.addr.2022.114280_b1715","unstructured":"The Path To A Regenerative Medicine Cure, n.d."},{"key":"10.1016\/j.addr.2022.114280_b1720","unstructured":"Sernova - Press Release, (n.d.). https:\/\/sernova.com\/press\/release\/?id=328 (accessed February 4, 2022)."},{"key":"10.1016\/j.addr.2022.114280_b1725","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1016\/j.actbio.2019.05.051","article-title":"Engineering the vasculature for islet transplantation","volume":"95","author":"Bowers","year":"2019","journal-title":"Acta Biomater."},{"key":"10.1016\/j.addr.2022.114280_b1730","doi-asserted-by":"crossref","first-page":"2100820","DOI":"10.1002\/advs.202100820","article-title":"Design Considerations for Macroencapsulation Devices for Stem Cell Derived Islets for the Treatment of Type 1 Diabetes","volume":"8","author":"Goswami","year":"2021","journal-title":"Adv. Sci."},{"key":"10.1016\/j.addr.2022.114280_b1735","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.biomaterials.2019.04.017","article-title":"Oxygen generating biomaterial improves the function and efficacy of beta cells within a macroencapsulation device","volume":"210","author":"Coronel","year":"2019","journal-title":"Biomaterials."},{"key":"10.1016\/j.addr.2022.114280_b1740","article-title":"Engineering an Macroporous Oxygen-Generating Scaffold for Enhancing Islet Cell Transplantation within an Extrahepatic Site","author":"Liang","year":"2021","journal-title":"SSRN Electron. J."},{"key":"10.1016\/j.addr.2022.114280_b1745","article-title":"An inverse-breathing encapsulation system for cell delivery","volume":"7","author":"Wang","year":"2021","journal-title":"Sci. Adv."},{"key":"10.1016\/j.addr.2022.114280_b1750","doi-asserted-by":"crossref","first-page":"1735","DOI":"10.1111\/ajt.14642","article-title":"Transplantation of macroencapsulated human islets within the bioartificial pancreas \u03b2Air to patients with type 1 diabetes mellitus","volume":"18","author":"Carlsson","year":"2018","journal-title":"Am. J. Transplant."},{"key":"10.1016\/j.addr.2022.114280_b1755","unstructured":"First-of-its-Kind Bio-Artificial Pancreas on Track for Type-I Diabetes Cure | Cafepharma, (n.d.). http:\/\/www.cafepharma.com\/cpwire\/article\/First-of-its-Kind-Bio-Artificial-Pancreas-on-Track-for-Type-I-Diabetes-Cure\/90161- (accessed June 18, 2020)."},{"key":"10.1016\/j.addr.2022.114280_b1760","doi-asserted-by":"crossref","unstructured":"L.H. Wang, A.U. Ernst, D. An, A.K. Datta, B. Epel, M. Kotecha, M. Ma, A bioinspired scaffold for rapid oxygenation of cell encapsulation systems, Nat. Commun. 2021 121. 12 (2021) 1\u201316. https:\/\/doi.org\/10.1038\/s41467-021-26126-w.","DOI":"10.1038\/s41467-021-26126-w"},{"key":"10.1016\/j.addr.2022.114280_b1765","doi-asserted-by":"crossref","first-page":"1905135","DOI":"10.1002\/adma.201905135","article-title":"An Atmosphere-Breathing Refillable Biphasic Device for Cell Replacement Therapy","volume":"31","author":"An","year":"2019","journal-title":"Adv. Mater."},{"key":"10.1016\/j.addr.2022.114280_b1770","doi-asserted-by":"crossref","DOI":"10.1177\/2041731420924818","article-title":"Safety and function of a new pre-vascularized bioartificial pancreas in an allogeneic rat model","volume":"11","author":"Magisson","year":"2020","journal-title":"J Tissue Eng."},{"key":"10.1016\/j.addr.2022.114280_b1775","unstructured":"Defymed MailPan, (n.d.). https:\/\/defymed.com\/mailpan\/."},{"key":"10.1016\/j.addr.2022.114280_b1780","author":"Therapeutics","year":"2016","journal-title":"Defymed Enters Partnership with Semma Therapeutics"},{"key":"10.1016\/j.addr.2022.114280_b1785","unstructured":"ViaCyte Q&A: CRISPR Tx quick progress, ongoing diabetes trial, & more - The Niche, (n.d.). https:\/\/ipscell.com\/2019\/09\/viacyte-qa-crispr-tx-quick-progress-ongoing-diabetes-trial-more\/ (accessed April 23, 2020)."},{"key":"10.1016\/j.addr.2022.114280_b1790","unstructured":"A Safety, Tolerability, and Efficacy Study of VC-01TM Combination Product in Subjects With Type I Diabetes Mellitus (Identification No. NCT02239354), (n.d.). https:\/\/clinicaltrials.gov\/ct2\/show\/NCT02239354?term=viacyte&draw=2&rank=4."},{"key":"10.1016\/j.addr.2022.114280_b1795","unstructured":"One-Year Follow-up Safety Study in Subjects Previously Implanted With VC-01TM (Identification No. NCT02939118), (n.d.). https:\/\/clinicaltrials.gov\/ct2\/show\/record\/NCT02939118?term=viacyte&draw=2&rank=3."},{"key":"10.1016\/j.addr.2022.114280_b1800","unstructured":"A Study to Evaluate Safety, Engraftment, and Efficacy of VC-01 in Subjects With T1 Diabetes Mellitus - Full Text View - ClinicalTrials.gov, (n.d.). https:\/\/clinicaltrials.gov\/ct2\/show\/study\/NCT04678557 (accessed March 3, 2021)."},{"key":"10.1016\/j.addr.2022.114280_b1805","doi-asserted-by":"crossref","first-page":"2102852","DOI":"10.1002\/adma.202102852","article-title":"A Zwitterionic Polyurethane Nanoporous Device with Low Foreign-Body Response for Islet Encapsulation","volume":"33","author":"Liu","year":"2021","journal-title":"Adv. Mater."},{"key":"10.1016\/j.addr.2022.114280_b1810","unstructured":"CRISPR Therapeutics and ViaCyte Present Positive In Vitro Data Towards a Potential Immune-Evasive Cell Replacement Therapy for Diabetes at EASD 2019 Nasdaq:CRSP, (n.d.). https:\/\/www.globenewswire.com\/news-release\/2019\/09\/17\/1916528\/0\/en\/CRISPR-Therapeutics-and-ViaCyte-Present-Positive-In-Vitro-Data-Towards-a-Potential-Immune-Evasive-Cell-Replacement-Therapy-for-Diabetes-at-EASD-2019.html (accessed June 19, 2020)."},{"key":"10.1016\/j.addr.2022.114280_b1815","unstructured":"CRISPR Therapeutics and ViaCyte, Inc. Announce First Patient Dosed in Phase 1 Clinical Trial of Novel Gene-Edited Cell Replacement Therapy for Treatment of Type 1 Diabetes (T1D) - ViaCyte, (n.d.). https:\/\/viacyte.com\/press-releases\/crispr-therapeutics-and-viacyte-inc-announce-first-patient-dosed-in-phase-1-clinical-trial-of-novel-gene-edited-cell-replacement-therapy-for-treatment-of-type-1-diabetes-t1d\/ (accessed February 4, 2022)."},{"key":"10.1016\/j.addr.2022.114280_b1820","unstructured":"An Open-Label, FIH Study Evaluating the Safety and Tolerability of VCTX210A Combination Product in Subjects With T1D - Full Text View - ClinicalTrials.gov, (n.d.). https:\/\/clinicaltrials.gov\/ct2\/show\/study\/NCT05210530?term=vctx210&draw=2&rank=1 (accessed February 4, 2022)."},{"key":"10.1016\/j.addr.2022.114280_b1825","unstructured":"AgeX Therapeutics, Inc. - AgeX Therapeutics and Sernova to Collaborate to Engineer Universal Locally Immune Protected Cell Therapies for Type I Diabetes and Hemophilia A, (n.d.). https:\/\/investors.agexinc.com\/news\/news-details\/2020\/AgeX-Therapeutics-and-Sernova-to-Collaborate-to-Engineer-Universal-Locally-Immune-Protected-Cell-Therapies-for-Type-I-Diabetes-and-Hemophilia-A\/default.aspx (accessed March 3, 2021)."},{"key":"10.1016\/j.addr.2022.114280_b1830","unstructured":"Sernova Enters into Exclusive Worldwide License Agreement with University of Miami for Therapeutic Cell Immune Protection Technologies, (n.d.). https:\/\/www.thenewswire.com\/press-releases\/1knDFRlMn-sernova-enters-into-exclusive-worldwide-license-agreement-with-university-of-miami-for-therapeutic-cell-immune-protection-technologies.html (accessed August 24, 2021)."},{"key":"10.1016\/j.addr.2022.114280_b1835","doi-asserted-by":"crossref","DOI":"10.1073\/pnas.2101258118","article-title":"A therapeutic convection\u2013enhanced macroencapsulation device for enhancing \u03b2 cell viability and insulin secretion","volume":"118","author":"Yang","year":"2021","journal-title":"Proc. Natl. Acad. Sci."},{"key":"10.1016\/j.addr.2022.114280_b1840","doi-asserted-by":"crossref","unstructured":"B.L. Strand, A.E. Coron, G. Skjak-Braek, Current and Future Perspectives on Alginate Encapsulated Pancreatic Islet, (n.d.). https:\/\/doi.org\/10.1002\/sctm.16-0116.","DOI":"10.1002\/sctm.16-0116"},{"key":"10.1016\/j.addr.2022.114280_b1845","doi-asserted-by":"crossref","first-page":"345","DOI":"10.1038\/nbt.3462","article-title":"Combinatorial hydrogel library enables identification of materials that mitigate the foreign body response in primates","volume":"34","author":"Vegas","year":"2016","journal-title":"Nat. Biotechnol."},{"key":"10.1016\/j.addr.2022.114280_b1850","unstructured":"Lilly, Sigilon Launch Up-to-$473M+ Type 1 Diabetes Partnership, (n.d.). https:\/\/www.genengnews.com\/topics\/drug-discovery\/lilly-sigilon-launch-up-to-473m-type-1-diabetes-partnership\/ (accessed April 22, 2020)."},{"key":"10.1016\/j.addr.2022.114280_b1855","unstructured":"Interview with Devyn Smith PhD, COO of Sigilon Therapeutics | Medgadget, (n.d.). https:\/\/www.medgadget.com\/2018\/03\/interview-devyn-smith-phd-coo-sigilon-therapeutics.html (accessed June 22, 2020)."},{"key":"10.1016\/j.addr.2022.114280_b1860","doi-asserted-by":"crossref","unstructured":"A.L. Hillberg, K. Kathirgamanathan, J.B. Lam, L.Y. Law, O. Garkavenko, R.B. Elliott, Improving alginate-poly-L-ornithine-alginate capsule biocompatibility through genipin crosslinking, J. Biomed. Mater. Res. - Part B Appl. Biomater. 101 B (2013) 258\u2013268. https:\/\/doi.org\/10.1002\/jbm.b.32835.","DOI":"10.1002\/jbm.b.32835"},{"key":"10.1016\/j.addr.2022.114280_b1865","unstructured":"current-partnerships @ lctglobal.com, (n.d.). https:\/\/lctglobal.com\/current-partnerships."},{"key":"10.1016\/j.addr.2022.114280_b1870","unstructured":"Diatranz Otsuka Ltd, (n.d.). http:\/\/dolglobal.com\/diabecell (accessed April 16, 2020)."},{"key":"10.1016\/j.addr.2022.114280_b1875","doi-asserted-by":"crossref","unstructured":"Q. Liu, A. Chiu, L.-H. Wang, D. An, M. Zhong, A.M. Smink, B.J. De Haan, P. De Vos, K. Keane, A. Vegge, E.Y. Chen, W. Song, W.F. Liu, J. Flanders, C. Rescan, L. Groth Grunnet, X. Wang, M. Ma, Zwitterionically modified alginates mitigate cellular overgrowth for cell encapsulation, (n.d.). https:\/\/doi.org\/10.1038\/s41467-019-13238-7.","DOI":"10.1038\/s41467-019-13238-7"},{"key":"10.1016\/j.addr.2022.114280_b1880","doi-asserted-by":"crossref","DOI":"10.1038\/s41551-018-0273-3","article-title":"glucose monitor by coating the sensor with a zwitterionic polymer","volume":"2","author":"Xie","year":"2018","journal-title":"Nat. Biomed. Eng."},{"key":"10.1016\/j.addr.2022.114280_b1885","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1016\/j.stemcr.2019.11.004","article-title":"Conformal Coating of Stem Cell-Derived Islets for \u03b2 Cell Replacement in Type 1 Diabetes","volume":"14","author":"Stock","year":"2020","journal-title":"Stem Cell Reports."},{"key":"10.1016\/j.addr.2022.114280_b1890","doi-asserted-by":"crossref","first-page":"590","DOI":"10.1111\/ajt.14547","article-title":"Immunoisolation of murine islet allografts in vascularized sites through conformal coating with polyethylene glycol","volume":"18","author":"Manzoli","year":"2018","journal-title":"Am. J. Transplant."},{"key":"10.1016\/j.addr.2022.114280_b1895","doi-asserted-by":"crossref","unstructured":"A.U. Ernst, D.T. Bowers, L.-H. Wang, K. Shariati, M.D. Plesser, N.K. Brown, T. Mehrabyan, M. Ma, Nanotechnology in cell replacement therapies for type 1 diabetes, (n.d.). https:\/\/doi.org\/10.1016\/j.addr.2019.01.013.","DOI":"10.1016\/j.addr.2019.01.013"},{"key":"10.1016\/j.addr.2022.114280_b1900","unstructured":"Removable implant may control type 1 diabetes, (n.d.). https:\/\/news.cornell.edu\/stories\/2018\/01\/removable-implant-may-control-type-1-diabetes."},{"key":"10.1016\/j.addr.2022.114280_b1905","unstructured":"Open-label Investigation of the Safety and Effectiveness of DIABECELL(R) in Patients With Type I Diabetes Mellitus (Identification No. NCT00940173), (n.d.). https:\/\/clinicaltrials.gov\/ct2\/show\/NCT00940173?term=diabecell&cond=Type+1+Diabetes&draw=2&rank=3."},{"key":"10.1016\/j.addr.2022.114280_b1910","unstructured":"Open-label Investigation of the Safety and Effectiveness of DIABECELL\u00ae in Patients With Type 1 Diabetes Mellitus (Identification No. NCT01739829), (n.d.). https:\/\/clinicaltrials.gov\/ct2\/show\/record\/NCT01739829?term=diabecell&cond=Type+1+Diabetes&draw=2&rank=2."},{"key":"10.1016\/j.addr.2022.114280_b1915","unstructured":"Open-label Investigation of the Safety and Efficacy of DIABECELL in Patients With Type 1 Diabetes Mellitus (Identification No. NCT01736228), (n.d.). https:\/\/clinicaltrials.gov\/ct2\/show\/record\/NCT01736228?term=living+cell+technologies&cond=Type+1+Diabetes&draw=2&rank=1&view=record."},{"key":"10.1016\/j.addr.2022.114280_b1920","unstructured":"A Safety, Tolerability and Efficacy Study of Sernova\u2019s Cell PouchTM for Clinical Islet Transplantation (Identification No. NCT03513939), (n.d.). https:\/\/clinicaltrials.gov\/ct2\/show\/study\/NCT03513939?term=cell+pouch&draw=2&rank=1."},{"key":"10.1016\/j.addr.2022.114280_b1925","unstructured":"Sernova Press, (n.d.). https:\/\/www.sernova.com\/press\/ (accessed March 25, 2020)."},{"key":"10.1016\/j.addr.2022.114280_b1930","unstructured":"An Open Label, Pilot Investigation, to Assess the Safety and Efficacy of Transplantation of Macro-encapsulated Human Islets Within the Bioartificial Pancreas Beta-Air in Patients With Type 1 Diabetes Mellitus (Identification No. NCT02064309), (n.d.). https:\/\/clinicaltrials.gov\/ct2\/show\/study\/NCT02064309."},{"key":"10.1016\/j.addr.2022.114280_b1935","unstructured":"Tidepool, (n.d.). https:\/\/www.tidepool.org\/blog\/what-ace-pump-means-for-tidepool-loop (accessed January 6, 2020)."},{"key":"10.1016\/j.addr.2022.114280_b1940","doi-asserted-by":"crossref","first-page":"58","DOI":"10.17925\/USE.2010.06.1.58","article-title":"Progress with closed-loop systems in type 1 diabetes","volume":"6","author":"Leelarathna","year":"2010","journal-title":"US Endocrinol."},{"key":"10.1016\/j.addr.2022.114280_b1945","unstructured":"EoFlow News, (n.d.). http:\/\/www.eoflow.com\/eng\/news\/news_010100.html?bmain=view&uid=77 (accessed January 6, 2020)."},{"key":"10.1016\/j.addr.2022.114280_b1950","unstructured":"Medtronic Receives FDA Breakthrough Designation for Developing Personalized Closed Loop Insulin Pump System for Diabetes Management, (n.d.). https:\/\/news.medtronic.com\/2019-02-19-Medtronic-Receives-FDA-Breakthrough-Designation-for-Developing-Personalized-Closed-Loop-Insulin-Pump-System-for-Diabetes-Management (accessed February 21, 2022)."},{"key":"10.1016\/j.addr.2022.114280_b1955","doi-asserted-by":"crossref","first-page":"eaax7043","DOI":"10.1126\/scirobotics.aax7043","article-title":"An actuatable soft reservoir modulates host foreign body response","volume":"4","author":"Dolan","year":"2019","journal-title":"Sci. Robot."},{"key":"10.1016\/j.addr.2022.114280_b1960","doi-asserted-by":"crossref","first-page":"2625","DOI":"10.1111\/ajt.16039","article-title":"Islet cell transplantation hits a milestone","volume":"21","author":"Pullen","year":"2021","journal-title":"Am. J. Transplant."},{"key":"10.1016\/j.addr.2022.114280_b1965","doi-asserted-by":"crossref","first-page":"1182","DOI":"10.1111\/tri.13930","article-title":"US food and drug administration (FDA) panel endorses islet cell treatment for type 1 diabetes: A pyrrhic victory?","volume":"34","author":"Piemonti","year":"2021","journal-title":"Transpl. Int."},{"key":"10.1016\/j.addr.2022.114280_b1970","first-page":"144","article-title":"Lessons from Human Islet Transplantation Inform Stem Cell-Based Approaches in the Treatment of Diabetes","author":"Triolo","year":"2021","journal-title":"Front. Endocrinol. (Lausanne)."}],"container-title":["Advanced Drug Delivery Reviews"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0169409X22001703?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0169409X22001703?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,30]],"date-time":"2025-09-30T05:18:18Z","timestamp":1759209498000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0169409X22001703"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,6]]},"references-count":393,"alternative-id":["S0169409X22001703"],"URL":"https:\/\/doi.org\/10.1016\/j.addr.2022.114280","relation":{},"ISSN":["0169-409X"],"issn-type":[{"value":"0169-409X","type":"print"}],"subject":[],"published":{"date-parts":[[2022,6]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Medical devices, smart drug delivery, wearables and technology for the treatment of Diabetes Mellitus","name":"articletitle","label":"Article Title"},{"value":"Advanced Drug Delivery Reviews","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.addr.2022.114280","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2022 The Author(s). Published by Elsevier B.V.","name":"copyright","label":"Copyright"}],"article-number":"114280"}}